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Abstract 
 
Argonaute (Ago) proteins are key components of small RNA-guided gene silencing 
pathways. They interact with small non-coding RNAs, which guide them to specific RNA 
targets and are therefore referred as guide RNA. Some Ago proteins cleave RNA targets, 
which are perfect complementary to the bound guide RNA. In case of partial 
complementarity between guide and target RNA, Ago proteins recruit additional factors to 
mediate translational repression and mRNA degradation.  
With such an important role in small RNA-guided gene silencing, it is necessary to 
understand the regulation of Ago proteins. Post-translational modifications, in particular 
phosphorylations, are an essential tool for protein regulation. Therefore, phosphorylations 
of Ago proteins from different species were analyzed using mass spectrometry. Here, 
multiple endogenous and highly conserved phosphorylation sites were identified. Moreover, 
five of them were organized in a phosphorylation cluster. This phosphorylation cluster was 
analyzed further regarding functionality and modifying enzymes. It turned out that this 
phosphorylation cluster is required for efficient target release and it is essential for early 
development C. elegans. By analyzing mass spectrometry data, one phosphatase was 
identified to be involved in the de-phosphorylation of this phosphorylation cluster. 
Mis-regulated Ago expression levels or mutations of Ago proteins are known to result in 
various diseases or cancer. A collaboration partner found different heterozygous Ago2 
mutations in patients showing the same neurological phenotype. In the second part of this 
thesis, all these detected mutations were characterized and checked regarding similarities. 
Here, a common mis-regulation in target release was revealed and sheds light on the 
unexpected finding that heterozygous Ago2 mutations lead to neurodevelopmental disease.  
 
 
  
 
 
Zusammenfassung 
 
Argonaut (Ago)-Proteine zählen zu den Schlüsselkomponenten der kleinen RNS-gesteuerten 
Genstilllegung. Diese Proteine interagieren mit kleinen-nicht kodierenden RNS, die sie zu 
spezifischen Ziel-RNS leiten und deshalb als Führungs-RNS bezeichnet werden. Einige Ago 
Proteine sind in der Lage Ziel-RNAs zu spalten, die zu den Führungs-RNS perfekt 
komplementär sind. Im Falle einer nur teilweisen Komplementarität zwischen Führungs-
RNS und Ziel-RNS, rekrutieren Ago Proteine zusätzliche Faktoren, um die 
Translationsrepression und den mRNS-Abbau zu vermitteln.  
Mit dieser wichtigen Rolle bei der Genstilllegung mittels kleinen RNAs ist es notwendig, die 
Regulation von Ago Proteinen zu verstehen. Posttranslationale Modifikationen, 
insbesondere Phosphorylierungen, sind ein wesentliches Instrument für die 
Proteinregulierung. Daher wurden Phosphorylierungen von Ago Proteinen aus 
verschiedenen Spezies unter Verwendung von Massenspektrometrie analysiert. Hier 
konnten mehrere endogene und hochkonservierte Phosphorylierungsstellen identifiziert 
werden. Darüber hinaus waren fünf von diesen Phosphorylierungen in 
Phosphorylierungsclustern organisiert. Dieses wurde weiter auf Funktionalität und 
modifizierende Enzyme hin untersucht. Es stellte sich heraus, dass dieses 
Phosphorylierungscluster für eine effiziente Freisetzung der Ziel-RNS erforderlich ist und 
dass dieses auch für die frühe Entwicklung in C. elegans unerlässlich ist. Bei der Analyse der 
Daten generiert durch Massenspektrometrie wurde eine Phosphatase identifiziert, die an 
der Dephosphorylierung von diesem Phosphorylierungscluster beteiligt ist.  
Es ist bekannt, dass falsch regulierte Expressionsniveaus von Ago Proteinen oder deren 
Mutationen zu verschiedenen Erkrankungen oder Krebs führen können. Ein 
Kooperationspartner fand bei Patienten, die einen ähnlichen neurologischen Phänotypen 
aufweisen, verschiedene heterozygote Mutationen in Ago2. Im zweiten Teil dieser Arbeit 
wurden all diese nachgewiesenen Mutationen charakterisiert und auf Ähnlichkeiten 
überprüft. Hier konnte eine Fehlregulierung bei der Freigabe der Ziel-RNS aufgedeckt 
werden und Licht auf die unerwartete Feststellung werfen, dass heterozygote Ago2 
Mutationen zu einer neurologischen Erkrankung führen.  
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1 Introduction 
 
In 1998, Andrew Fire and Craig Mello discovered RNAi in C. elegans and 8 years later they 
received the Nobel Price for their groundbreaking discovery1. It was shown that the injection 
of double stranded (ds) RNA molecules can lead to silencing of complementary genes much 
better than single stranded (ss) RNA molecules1. Since then, key insights of the role of small, 
non-coding RNAs in different cellular processes have been unraveled.  
 
1.1 Small RNA classes and their biogenesis 
 
Small, non-coding RNAs that play roles in regulation of gene expression can be divided in 
three main classes based on the structure of the precursors, biogenesis, appearance, and 
mode of action. The classes are named microRNAs (miRNAs), small interfering RNAs (siRNAs) 
and the PIWI-interacting RNAs (piRNAs). They have their length of 20-35 nucleotides (nt) in 
common and that they are all loaded into a member of the Argonaute protein family. Loaded 
in Argonaute proteins (Ago), small RNAs guide the repression of gene expression in various 
organisms2–4. miRNAs are mainly transcribed by polymerase II or III and form a stem-loop 
structure, called primary-miRNA (pri-miRNA)5–7. The primary transcript is processed in the 
nucleus by the RNase III enzyme Drosha and cofactor DiGeorge syndrome critical region gene 
8 (DGCR8)8–11. The stem-loop structure is recognized by DGCR8 and Drosha crops the pri-
miRNA to generate precursor-miRNA (pre-miRNA)8–16. After the first processing step, pre-
miRNAs are exported by Exportin5 from the nucleus into the cytoplasm17–20. In the cytoplasm, 
a second processing step occurs mediated by the RNase III enzyme Dicer and its cofactors 
PACT (protein activator of the interferon-induced protein kinase) and TRBP (TAR RNA 
binding protein)21–28. PACT and TRBP recognize dsRNA and promote the substrate 
interaction29–33. The loop of the pre-miRNA is cut off and a small RNA duplex with a length of 
about 22 nt with 5’ phosphates and 2 nt 3’ overhangs is generated9,21,22,34–38. One strand (guide 
strand) is bound by Ago (see chapter 1.2.1). The other strand of this intermediate miRNA 
structure, often referred to as miRNA*, is removed from Ago and degraded in most cases2,39–
42 (Figure 1). Dicer, TRBP and Ago form a stable complex, which is referred to as loading 
complex of the RNA-induced silencing complex (RISC loading complex, RLC). This complex 
allows pre-miRNA processing and Ago-loading21,23–25.  
Introduction 
 
siRNAs are independent of Drosha cleavage and are processed by the RNase III enzyme Dicer 
from long, dsRNAs to about 21 nt long RNA duplexes. Their sources can be exogenous (exo-
siRNAs) or endogenous (endo-siRNAs). Exo-siRNAs can be generated by the cleavage of viral 
RNAs. Endo-siRNAs derive for example from transposable elements, natural antisense 
transcripts or hairpin RNAs43–46. The duplexes are composed of a guide strand, which is 
perfectly complementary to its target (antisense strand), and the complementary passenger 
strand (sense strand)3. Like miRNAs, siRNA duplexes are separated and the guide is 
incorporated into the RISC (Figure 1). This strand guides the complex to perfect 
complementary targets, which are cleaved by sequence-specifically RISC. The passenger 
strand is unstable and degraded after unwinding2–4. In contrast to the biogenesis of miRNAs 
or siRNAs, piRNAs originate from ssRNA precursors47. They are transcribed from large piRNA 
clusters, which also represent a pool of transposon sequences4,47. piRNAs are associated with 
a member of the PIWI clade of the Argonaute protein family and are exclusively expressed in 
the germline where they silence transposons48,49.  
 
 
Figure 1 miRNA/siRNA biogenesis pathway. miRNAs are transcribed by RNA polymerase II or III to form stem-
loop structures, called pri-miRNA. In the nucleus, a first processing step to pre-miRNA takes place, which is 
performed by Drosha and its cofactor DGCR8 (cleavage sites are marked by arrowheads). After export into the 
cytoplasm by Exportin5, the precursor is processed a second time. Dicer and its cofactor TRBP cut off the loop 
(cleavage sites are marked by arrowheads). siRNAs derived from exogenous or endogenous sources are also 
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processed by Dicer. One strand of the duplex is then incorporated into Ago proteins. In case of perfect 
complementarity, Ago2 in humans can cleave the mRNA. In case of partial complementarity between guide RNA 
and target RNA, GW182 proteins are recruited. These proteins serve as binding platforms for other proteins or 
complexes which lead to translational repression and destabilization8,9,50–52. 
 
1.2 Argonaute proteins 
 
Argonaute proteins play an essential role in small RNA-guided gene silencing. They are 
specialists in binding small RNAs, which guide them to the targets. Argonaute proteins are 
named after the characteristic phenotype of an Ago-knockout in Arabidopsis thaliana that 
looks like the octopus Argonauta argo53. Argonaute proteins can be found in various organism 
but differ in their number. For example, there are twenty-six Ago proteins present in 
Caenorhabditis elegans (C. elegans), ten in Arabidopsis thaliana, eight in mammalia, five in 
Drosophila melanogaster and one in Schizosaccharomyces pombe2. The Argonaute protein 
family can be classified in three clades: The Ago proteins, referred after Ago1 of Arabidopsis 
thaliana, the PIWI proteins, named after PIWI of Drosophila melanogaster, and the worm-
specific WAGO proteins54–56. Four of the eight mammalian Ago proteins are part of the PIWI 
subfamily, called HIWI1-3 and HILI, the remaining four Ago proteins belong to the Ago clade, 
and are termed Ago1-44. PIWI proteins are mainly expressed in the germline and interact with 
piRNAs to protect the genome from mobile genetic elements via transcriptional silencing 
processes47,57,58. The members of the Ago protein clade are ubiquitously expressed and key 
players of the small RNA-guided gene silencing pathway. Some of them are able to silence 
targets or to mediate target repression by endonucleolytic cleavage (see chapter 1.2.1). 
Another way to achieve silencing is the recruitment of other factors that destabilize the target 
RNA59,60 (see chapter 1.4). In addition, Argonaute proteins are present in archaea and 
bacteria. Bacterial and archaeal Ago proteins show a domain organization, which similar to 
the eukaryotic Ago proteins61–64. Of note, all characterized Ago proteins in prokaryotes target 
DNA, indicating that they are involved in DNA silencing61–63,65–68. Some studies hypothesized 
that prokaryotic Ago proteins are involved in protection against invasive genetic 
elements63,67,69.  
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1.2.1 Functional domains of Ago proteins 
 
Ago proteins are two-lobe proteins, which comprise four different domains: the (N)-terminal 
domain, the Piwi-Argonaute-Zwille (PAZ) domain, the middle (MID) domain and the P-
element-induced wimpy testes (PIWI) domain (Figure 2). Two linkers (L1 and L2) link the N-
terminal with the PAZ and the MID with the PIWI domain. The 3’ nucleotide of the small RNA 
is bound by the PAZ domain, its 5’ end anchors in the MID and PIWI domain68,70–72.  
 
 
Figure 2 Crystal structure of human Ago2.  (A) Domain organization of human Ago2. Color code: N domain – 
blue, PAZ – dark green, MID – magenta, PIWI – yellow, linker domains - grey (B)/(C) Crystal structure of human 
Ago2 with co-crystalized miRNA (orange) and parts of mRNA (light green). The domains are indicated like (A). 
The 5’ end of the miRNA anchors in the MID domain, its 3’ end is bound to the PAZ domain. The structure is based 
on the model 4W5O73.  
 
Ago proteins associate with one strand of the miRNA duplex. In consequence, there must be 
a mechanism to unwind the duplex and to decide, which strand is bound by Ago. It is 
suggested that the N-terminal domain functions as the initiator for duplex unwinding of the 
miRNA during RISC assembly74. But the detailed mechanism of duplex-unwinding is not 
completely clear. The stability of the miRNA ends is one important determinant for strand 
selection, which is called ‘asymmetry rule’. The strand with the less thermodynamically stable 
5’-terminus is preferentially loaded into Ago 75,76.  
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The PIWI domain contains an RNase-H like fold that catalyzes cleavage of complementary 
RNA targets endonucleolytically, a process often referred to as ‘slicing’56. This slicing ability 
is based on a catalytic center, which contains a tetrade of Asp-Glu-Asp-His70. Only human Ago2 
is able to cleave targets in case of fully complementarity between guide and target RNA77,78. 
In addition to its slicing function, the PIWI domain contains two binding pockets, which allow 
for binding to a member of the glycine-tryptophan protein of 182 kDa (GW182) protein 
family50,71.  
 
1.2.2 Binding of guide and target RNA 
 
Small RNAs are bound by Ago proteins via their phosphate-sugar backbone. This is the basis 
for guide target interaction, because the bases of the guide RNA protrude into the binding 
channel for target RNA68,71. Experiments of the DNA-binding Ago protein of Thermus 
thermophilus showed that base pairing of the guide strand at positions 4-16 is necessary for 
DNA cleavage. Only mismatches between position 2-8 reduced cleavage activity and 
mismatches at the cleavage site abolished slicing function because the catalytic center is not 
reached79.  
The position 2-8 is referred to as seed sequence and its complementarity is the main criterion 
for target-site prediction in the miRNA pathway72,80–83. Overall, miRNA target sites are located 
in the 3’ UTR of mRNAs83. Structural investigations revealed that the strongest canonical 
target sites with seed complementarity contain an adenine opposite the first nucleotide of the 
guide. This adenine is recognized by a specific binding pocket within Ago proteins73,81,84. 
Target recognition occurs in two steps: first, the seed nucleotides 2-6 are pre-organized by 
MID and PIWI domains, resulting in a stacked and helical conformation with exposed 
nucleotides 2-471. This enables a fast and primary binding but it only leads to stable target 
binding, when the sites are complementary to the full miRNA seed85. With no full 
complementary seed, Ago either laterally diffuses along the mRNA to scan for potential 
targets or dissociate completely85. Crosslinking of Ago and its targets revealed also non-
canonical targets, which do not have a full seed match86–89. Additionally to seed interaction, 
the guide’s 3’ end is also able to contribute to target recognition. Here, in particular the 
nucleotides 13-16 are involved81,90. Recent publications have shown that also the 3’ half of the 
guide can direct the miRNA family members with the same seed to different target sites in C. 
elegans91 and mouse brain86. 
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1.3 GW182 proteins and their interaction with Ago proteins 
 
In mammals, only a minor part of miRNA-guided gene silencing is based on endonucleolytic 
cleavage of target RNAs. The main part depends on Ago-miRNA binding to 3’ UTR and gene 
silencing through translational repression and mRNA decay of partially complementary 
target RNAs92,93. To fulfill these duties, Ago proteins recruit GW182 proteins24,94–96. GW182 
proteins are large and unstructured proteins, which in humans are referred to as 
trinucleotide repeat-containing protein 6 A, B, C (TNRC6A-C). They serve as binding platforms 
for other effector complexes that are required for repression24,97 (see chapter 1.4, Figure 3). 
Of note, GW182 proteins can repress a reporter gene without Ago, when artificially tethered 
to a target by recruiting effector complexes, which are responsible for deadenylation and 
decapping of the target RNA, indicating that this step is independent of Ago98. It is assumed 
that translational repression and/or storage is performed in structured protein networks of 
various size called processing bodies (p-bodies)94,99–101.  
 
1.3.1 Molecular basis of Ago-GW182 binding 
 
The three human GW182 paralogs are structurally similar. They consist of two main regions, 
an unstructured N-terminal Ago binging domain and the C-terminal silencing domain. The 
silencing domain mediates the recruitment of mRNA deadenylation machinery like CCR4-
NOT or PAN2-PAN3102–104 (see chapter 1.4). As their name suggests, GW182 proteins contain 
many glycine-tryptophan (GW)-repeats, distributed over the whole protein50,92,102,105. 
Deadenylase complexes CCR4-NOT and PAN2-PAN3 are bound by tryptophans of GW182 
proteins103,104,106. In addition, Ago proteins interact also with tryptophans of GW182 proteins. 
Several binding sites for Ago could be identified in TNRC6, but only two Ws in the region 
comprising residues 599-683 in TNRC6B might be important for binding50,107. In contrast, a 
recent study reported three Ago proteins that are interacting with TNRC6A at the same time 
at three different motifs with high affinity108. Notably, all four human Ago proteins can be 
bound in the same fashion107,109–112. It is suggested that the Ws need 10 specific amino acids, 
which serve as spacers between the two Ws, for efficient Ago binding50,107.  
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1.4 Mechanism of GW182-mediated repression 
 
GW182 proteins interact with polyadenylate-binding protein (PABP) and thereby recruit the 
poly(A)-nuclease deadenylation complex subunit 2 (PAN2)-PAN3 and the carbon catabolite 
repressor protein 4 (CCR4)-NOT complexes (Figure 3)98,102–104,113. These recruitments 
catalyze deadenylation of the mRNA. Deadenylation is followed by decapping by mRNA-
decapping enzyme subunit 1 (DCP1)-DCP2 complex113. The loss of the cap enables rapid 
degradation by the 5’-3’ exoribonuclease 1 (XRN1)114. In addition, the recruitment of the 
CCR4-NOT complex also leads to translational repression. The CCR4-NOT complex recruits 
probable ATP-dependent RNA helicase (DDX6), which inhibits translation (Figure 3)92,115.  
In addition, translational repression occurs through inhibition of translation initiation. The 
eukaryotic initiation factor 4A (eIF4A) is an RNA helicase that is needed for unwinding of 
secondary structures within the 5’ UTR of mRNAs116. This process is necessary for the 
ribosomal scanning, wherein the small ribosomal subunit attaches to the 5’-end of the target 
RNA and then searches for the start codon116,117. There are discrepancies about the 
mechanisms of the interference with eIF4AI/II but the consensus suggest that miRNA indicate 
the dissociation of these factors from the mRNA72,92,118–120. This might lead to blocking of the 
ribosomal scanning process and the assembly to eIF4F complex, which is composed of the 
eIF4A (eIF4AI/II), the eukaryotic initiation factor 4G (eIF4G) and the eukaryotic initiation 
factor 4E (eIF4E)72,92,118–120. In Drosophila, translational repression was also reported to be 
independent of GW182 proteins118. This underlines that the detailed molecular mechanisms 
of miRNA-guided gene silencing are still not fully understood.  
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Figure 3 Schematic model of miRNA-mediated gene silencing in animals. Ago proteins are guided by miRNA 
to their target mRNAs and GW182 proteins are recruited, which bind via two tryptophans to the binding pockets 
of Ago. GW182 proteins interact with PABP, the cytoplasmic deadenylase complexes PAN2-PAN3 and CCR4-NOT. 
These complexes promote deadenylation of the mRNA. After deadenylation, decapping and degradation occurs. 
Additionally, translation is repressed. Therefore, miRNAs block translational initiation by interfering with the 
activity of eukaryotic initiation factor 4F (eIF4F) complex. The cap structure is shown as a black circle. PABP-
interacting motif is depicted in red. (modified from 92) 
 
1.5 Post-translational modifications of Ago proteins 
 
It is known that Ago proteins are post-translationally modified at multiple sites and in many 
ways, e.g. by ubiquitination, hydroxylation, SUMOylation, PARylation and phosphorylation.  
Ubiquitinations of Ago proteins leads to destabilization by the ubiquitin-proteasome pathway 
and were detected in mouse embryonic stem cells and also in Drosophila Ago1121,122. One 
reported E3 ubiquitin ligase interacting with Ago is mLin41 (Trim71) and is involved in the 
regulation of Ago2 turnover122. Empty Drosophila Ago1 is selectively ubiquitinated by the 
RING-type E3 ubiquitin ligase Iruka (Iru) to trigger its degradation and to ensure correct Ago 
function121. The reduction of the abundance of Drosophila Ago1 and mouse Ago2 is regulated 
by the ubiquitin-proteasome system123. Additionally, Ago1 and Ago2 are reported to be 
downregulated during T cell activation by ubiquitination and proteasomal degradation124. In 
addition, SUMOylations are known to regulate Ago proteins. Here, a member of the SUMO 
(small ubiquitin-like modifier) family is attached to lysines of specific proteins125. 
SUMOylation at position L402 of Ago2, has been reported by two labs but with contrary 
effects: on the one hand it is suggested that SUMOylation leads to destabilization of Ago2126, 
on the other hand it might be required for full Ago2 siRNA-mediated activity127(Figure 4). In 
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contrast, an increase of Ago2 stability in mouse and human cells has been observed with a 
hydroxylation at proline (P) 700128. This hydroxyl group is attached to Ago2 by the type I 
collagen prolyl-4 hydroxylase128. Both, mutation of P700 to A and depletion of the 
hydroxylase result in destabilization of Ago2, indicating a link between hydroxylation and 
protein stability128. Because the P700 position is located close to a W-binding pocket in Ago2 
that ensures an interaction with TNRC6 proteins71,108, it remains speculative if the 
hydroxylation at this position affect miRISC assembly72 (Figure 4). In human cells, all Ago 
proteins undergo poly (ADP-ribosylation) (PARylation)129. Poly(ADP-ribose) (PAR) is an 
important regulatory molecule in the nucleus and regulates transcription, chromosome 
structure and DNA damage repair. This macromolecule is also reported to be added to Asp 
(D), Glu (E) and Lys (K) residues of Ago proteins. PARylation is involved in stress regulation, 
especially in the formation of cytoplasmic stress granules and therefore regulates mRNA 
translation and stability 129,130. It has been published that PARylation of Ago proteins reduced 
translational repression and slicer activity, which might come from an impeded target 
accessibility129. In addition, downregulated RNAi activity was monitored shortly after viral 
infection via PARylation of the RISC131 (Figure 4). 
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Figure 4 Post-translational modifications of Ago2.  Phosphorylation of Y529, which is located near the 5’ 
binding pocket of the miRNA in the MID domain, prevent the miRNA loading132. Phosphorylation of Y393 is located 
in the linker 2 region and reduces the levels of Ago2 associated miRNAs133,134. The neighboring phosphorylation 
of S387was published to be mediated by MAPKAPK2135 or AKT3136 in vitro. This phosphorylation is responsible 
for increased miRNA activity by stimulating the assembly of RISC. In addition, it leads to the translocation of Ago2 
to multivesicular endosomes and secretion of exosomes137. Some other phosphorylations (S253, T303, T307 and 
S798) were identified but the function of these have not been assigned yet132. Additionally, modifications like 
hydroxylation at P700 were measured. This hydroxylation increases the Ago2 stability128. SUMOylation at K402 
was described either to destabilize Ago2126 or to be necessary for siRNA activity127. Also poly (ADP-ribosylation) 
(PARylation) was found, which blocks miRNA activity by decreasing target accessibility129,131. EGFR: epidermal 
growth factor receptor; OH: hydroxyl group; P: phosphate; PAR: poly (ADP-ribose); PARP: poly (ADP-ribose) 
polymerase; SUMO: small ubiquitin-like modifier; UBC9: ubiquitin carrier protein 9. Modified from 72. 
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1.5.1 Phosphorylation of Ago proteins 
 
Phosphorylations are probably among the best-investigated post-translational modifications. 
This might be due to its important role in various signaling pathways. Several phosphorylated 
sites were also found in Ago proteins.  
Some studies detected a phosphorylation at S387, which is located in the L2 region of 
Ago2132,135,136 (Figure 4). In vitro studies discovered MAP kinase-activated protein kinase 2 
(MAPKAPK2) in the p38 MAPK pathway-mediated stress response135 and the proto-oncogene 
RACγ serine/threonine-protein kinase (AKT3)136 to phosphorylate S387 in Ago2. Different 
results of localization within the cell are reported with the mutation of S387 into A in Ago2, 
which resembles a phospho-lacking mutant, indicating a not fully clear function of the 
phosphorylation in localization135,136,138. Phosphorylation at S387 is required for the 
interaction between Ago and LIM domain-containing protein 1. This protein bridges the Ago-
TNRC6 interaction139. S387A mutation and the resulting blocking of phosphorylation also 
minimize trafficking of Ago2-miRNA complexes to multivesicular endosomes and reduce the 
secretion of exosomes137. Taken together, the data indicate that phosphorylation supports 
miRNA function by stimulating the miRISC assembly72. 
A further well characterized phosphorylation is located at position tyrosine (Y) 393 in the L2 
region and neighboring to S387132–134(Figure 4). Hypoxic stress stimulates the 
phosphorylation at this residue and is modulated by epidermal growth factor receptor 
(EGFR)133. Another study revealed that overexpressed RAS reversibly blocks protein–
tyrosine phosphatase 1B. This inhibition leads to a hyper-phosphorylation of Ago2 at position 
Y393134. Both groups describe a reduced interaction between Ago and Dicer with a 
phosphorylation at Y393. In addition, phosphorylation at this position prevents miRNA 
loading of Ago2, impairs the regulation of p21 mRNA and induces senescence133,134. In the 
same line, phosphorylation of Ago2 at Y529 inhibits miRNA loading (Figure 4). This specific 
residue binds the 5’ phosphate and the first nucleotide of guide RNA71,140,141. Phosphorylation 
at Y529 prevents miRNA binding and is known to associate with reduced miRNA binding 
during macrophage activation142. Further phosphorylation sites were detected in the PAZ 
domain (S253, T303, T307) and in the PIWI domain (S798) but their functions still remain 
unknown (Figure 4)132. 
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1.5.2 The role of Ago2 in cancer and neurological disease 
 
It is known that miRNA regulation is critical in tumorgenesis. As the main interactor of 
miRNAs, an overexpression of Ago proteins were detected in several carcinomas, like colon 
cancer143, head and neck squamous cell cancer144, and glioma145. In these studies, a relation 
between Ago2 overexpression and tumor growth and survival of cancer patients could be 
revealed145,146. They also discovered that Ago2 was overexpressed in hepatocellular 
carcinoma tissues and cells and that the overexpression enables oncogenic miRNAs, e.g. miR-
21, to repress targets146,147. In contrast, the regulatory capacity of tumor suppressive miRNAs, 
like let-7, was unaffected146,147. In addition, a regulatory feedback loop was identified, in which 
miR-99a can inhibit Ago2 reciprocally. This miRNA was found to be remarkably decreased in 
hepatocellular carcinoma tissues146. Moreover, a decreased expression level of Ago2 protein 
but not mRNA was found in melanoma148,149. Additionally, reduced miRNA and siRNA 
functionality and phenotypic effects, like higher migration potential of melanoma cells were 
observed148. Interestingly, overexpression of Ago2 protein could block cell and tumor 
growth148,149. Due to different miRNA expression pattern in tissues and association of Ago2 
with various processes in cancer, the expression level of Ago2 is variable in different types of 
cancer150,151. According to The Cancer Genome Atlas (TCGA, www.cancergenome.nih.gov), 
various mutations of Ago2 were identified in cancers, e.g. the mutation S831P was found in 
melanoma.  
Despite cancer, a recent study uncovered an important role of Ago2 in neurological disease152. 
Pircs et al.152 published recently that in Huntington’s disease Ago2 accumulates as a result of 
impaired autophagy in neurons, which express aggregating mutant Huntingtin. The Ago2 
accumulation leads to a global alteration of miRNA activity152. Taken together, these 
observations of Ago2 levels and mutations in cancer and neurological disease indicate that 
the correct Ago2 expression level in different tissues and cells but also intact Ago2 proteins 
are essential in maintaining appropriate miRNA activity and to ensure health. 
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1.6 Aims of the thesis 
 
Ago proteins are central components of the small RNA-guided gene silencing pathway. To 
fulfill their functions, Ago proteins interact with small non coding RNAs, which guide them to 
specific target RNAs. On the one hand, some Ago proteins are endonucleolytically active and 
are therefore able to cleave their targets. On the other hand, Ago proteins recruit additional 
proteins and complexes to mediate translational repression and mRNA decay.  
Since Ago proteins play such a pivotal role in gene silencing, it is important to understand the 
regulation of these proteins by post-translational modifications. It’s already known that Ago 
proteins are targets for post-translational modifications. The best characterized modification 
on Ago proteins is phosphorylation. However, most phosphorylation sites were measured 
from overexpressed Ago proteins. The first focus of this thesis is the mass spectrometric 
identification of endogenous and conserved phosphorylation sites. Additionally, these 
phosphorylation sites will be characterized regarding their functionality and modifying 
enzymes will be identified. 
Mis-regulation in Ago expression levels or Ago mutations result in diseases, like Huntington’s 
disease or several cancers. A genome screening analysis of various patients showing the same 
neurological phenotype revealed different, heterozygous point mutations or deletions of 
Ago2. The second focus of this thesis is the functional characterization of these mutations.  
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2 Results 
2.1  Phosphorylation of endogenous Ago proteins 
 
As a key player of the gene silencing machinery, Ago proteins underlie extensive regulation. 
Many post-translational modifications of Ago proteins are known (see chapter 1.5), like 
ubiquitination, hydroxylation and phosphorylation. Here, a systematic and unbiased screen 
using different purification methods of endogenous Ago proteins are described, followed by 
the identification of phosphorylation sites using mass spectrometry.  
 
2.1.1 Identification of endogenous phosphorylations in Ago proteins 
 
Since overexpression of tagged proteins can lead to unspecific phosphorylation events, 
different purification strategies to purify endogenous Ago proteins from human cell lysates 
were established. On the one hand, a purification with specific monoclonal antibodies against 
Ago2 or a co-immunoprecipitation (co-IP) with antibodies against TNRC6 proteins was used. 
On the other hand, a purification strategy, termed Ago-APP (affinity purification by peptide) 
was chosen to precipitate all Ago proteins107,154. Shortly, for the immunoprecipitations, a 
specific monoclonal antibody against either Ago2 or TNRC6 proteins present in the cell lysate 
were coupled to protein-G sepharose beads. After washing, lysates, which contain 
phosphatase inhibitors, were added to the beads, followed by Ago protein elution and analysis 
using mass spectrometry. The second purification method, the Ago-APP, was performed with 
a short FLAG-GST-TNRC6B-peptide (T6B_599-683)107, which was coupled to anti-FLAG M2 
affinity agarose gel. The lysates were incubated on the affinity gel, washed, eluted with 
Lämmli-sample buffer and separated on a SDS-PAGE. Ago bands were excised and the 
samples were prepared for mass spectrometric analysis. The measurements were performed 
at least in triplicates. The overlapping potential phosphorylation sites are highlighted in 
Figure 5 A. The left part of this figure shows a Venn diagram with three biological replicates. 
The striped area represents the overlap of the phosphorylation sites of Ago in all three 
replicates. In the right part of this figure, the human Ago proteins are depicted schematically 
with their domain structure. Within this figure, the green bars represent the phosphorylation 
sites, which were measured in at least three biological replicates. The orange bars depict the 
phosphorylation sites measured in two biological replicates. Several phosphorylation sites 
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are highly conserved between the four human Ago proteins. At the N-terminus, there is one 
serine (S) as well as one tyrosin (Y), which were phosphorylated on the same peptide. The 
phosphorylation of a Y, in Ago2 the Y322, which is located in the PAZ domain seems to be 
phosphorylated in all four human Ago proteins.  
 
 
Figure 5 Identification and conservation of potential phosphorylation sites in Ago proteins. (A) Mass 
spectrometric measurements of human Ago proteins. Left: Venn diagram shows three replicates with an 
overlapping part, which is marked by stripes. Right: Schematic depiction of all four human Ago proteins and their 
domains. Green bars represent phosphorylation sites, which were measured at least in three biological replicates. 
The orange bars represent phosphorylation sites, which were measured in two biological replicates. Those 
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phosphorylation sites were detected via mass spectrometric analysis after an anti-TNRC6-IP or Ago-APP. (B) 
Endogenous Ago proteins were purified from human, mouse, rat, zebrafish and C. elegans with the indicated 
method. Here, SDS gels are shown which were stained with Coomassie. (C) Schematic representation of the Ago 
proteins and their domain structure of various species. The phosphorylation sites are shown as green bars 
(measured in at least three biological replicates) and orange (measured in two biological replicates). Hs: Homo 
sapiens, Mm: Mus musculus, Rn: Rattus norvegicus, Dr: Danio rerio, Ce: Ceanorhabditis elegans. The sample 
preparation of mouse, zebrafish and C. elegans were performed by Dr. Judith Hauptmann.  
 
Prominent phosphorylations, in which single amino acids were detected to be 
phosphorylated, is found between the residues 530 and 556. Lastly, a cluster phosphorylation 
at the very C-terminus with five potential residues from 824-834 could be identified up to 
four times phosphorylated at the same time and within the same peptide. These residues are 
very well conserved in all four human Ago proteins and appears in a phosphorylation cluster. 
Only Ago4 showed less phosphorylation sites but this might be due to low abundance of Ago4. 
The well-characterized phosphorylation site on S387 could only be detected in human Ago2 
in our measurements135,136,139. 
To see if those phosphorylation sites are also conserved between different species, material 
from mouse, rat, zebrafish and C. elegans was analyzed as described above (Figure 5 B). All 
phosphorylation events found on human Ago proteins were also found phosphorylated in 
these species except for Y322 and S136, which appeared to be human specific (Figure 5 C).  
Because of the high conservation, two multiple phosphorylations were analyzed further. First, 
the peptide around 555-561 (555:61) in human Ago2, which contains four potential residues 
but was only found to be single phosphorylated in each individual measurement but at 
different residues. These amino acids are located in the MID domain in close proximity to the 
binding pocket of the target mRNA that is opposite to the first nucleotide of the miRNA73,108. 
The second phosphorylation cluster was the 824-834 cluster (824:34). This cluster is located 
on an exposed and flexible loop, which is not resolved in the known human Ago2 crystal 
structure71.  
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2.1.2 Functional analysis of the 555:61 and 824:34 cluster phosphorylation of Ago2 
 
The 555:61 cluster contains four closely located potential phosphorylation sites, but only 
single phosphorylation events were measured on individual peptides (indicated by the 
individual boxes, Figure 6 A). In the phosphorylation cluster at residues 824:34, hyper-
phosphorylation of single peptides could be detected by mass spectrometry (indicated by one 
box, Figure 6 A). These phosphorylation events of single or multiple phosphorylated amino 
acids were readily detected in the spectra of mass spectrometry analysis (Figure 6 B and C). 
To learn more about those phosphorylated clusters and their potential functions, the 
phosphorylated residues were mutated into glutamate (E), a phospho-mimicking mutant, and 
into alanine (A), a non-phosphorylatable mutant, mimicking the unphosphorylated state.  
In a first experimental characterization, the constructs were fused to a Lambda N (λN)-
peptide and a HA-tag to physically tether them to a luciferase reporter mRNA containing the 
boxB RNA segment allowing for high affinity binding to λN 155,156 (Figure 6 D). Here, single as 
well as multiple mutants were analyzed. In this analysis, the single mutants behaved like wild-
type (WT) Ago2. Moreover, the cluster mutations which all have potential phosphorylated 
residues of 824:34 mutated into either E or A, did not show an effect in this tethering assay 
(Figure 6 D). This approach demonstrates that mutations in the cluster region did not abolish 
silencing activity and recruitment of downstream factors when artificially tethered to a 
reporter mRNA target using the λN/boxB system.  
Only the phospho-mimicking mutant, in which all residues of the 555:61 cluster were 
mutated to E, showed a strongly impaired silencing activity (Figure 6 D). This leads to the 
assumption that downstream factors of the gene silencing machinery cannot be recruited 
when artificially tethered to a reporter mRNA target using the λN/boxB system.  
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Figure 6 Phosphorylation cluster and their spectra. Schematic representation of human Ago2 and its domain 
structure. The blue individual boxes represent single phosphorylations on the residues 555-561. One blue box 
with the residues 824-834 indicates multiple phosphorylations on this peptide. (B) Representative CID fragment 
spectra of the mono phosphorylated at T556 of human Ago2 peptide (TpTPQTLSNLCLK). This spectrum originates 
from a LC-UHR-QTOF run. Monoisotopic mass: 1397.65 Da, Mascot ion score: 45, expectation value: 3.2e-005, Δ 
mass: 0.01 Da. (C) Spectra of a four times phosphorylated peptide of human Ago2 
(YHLVDKEHDpSAEGpSHTpSGQpSNGR). The phosphorylated sites are S824, S828, S831 and S834 according to 
Mascot. Monoisotopic mass: 2829.98 Da, Mascot ion score: 31, expectation value: 0.0085, Δ mass: 0.0017 Da. (D) 
Tethering assay with HA-tagged Ago2 wt and mutants. Renilla luciferase (RNL) activity was measured in extracts 
of HeLa cells. Cells were co-transfected with Ago2 constructs, either with or without λN-peptide, RNL-reporter 
with 5boxB aptamers, and Firefly (FF) luciferase. TNRC6A served as positive control. The expression levels of RNL 
was normalized to the FF signals (n ≥ 3, SEM). 
 
In a second approach, TNRC6 binding of Ago2 mutants was analyzed. TNRC6 proteins are the 
main interactors of Ago proteins in context of translational repression and mRNA decay. 
Therefore, FLAG/HA-tagged constructs immunopurified via anti-FLAG-IP. The beads with the 
coupled proteins were split for either RNA isolations, followed by Northern Blotting, or eluted 
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for Western Blot analysis. Co-precipitated TNRC6 proteins were detected by a specific anti-
TNRC6 antibody. The TNRC6 binding of the 555:61A mutant is undistinguishable from WT 
(Figure 7 A, lane 1-2). In contrast, the phospho-mimicking mutant showed an impaired 
interaction with TNRC6 (Figure 7 A, lane 3). The reduced TNRC6 binding results in impaired 
silencing activity, as additional factors like deadenylation and decapping complexes will not 
be recruited. Consistently, the reduced silencing activity could be seen in Figure 6 D. 
In a next assay, binding of miRNA was tested. Ago proteins need miRNAs to guide them to 
specific targets, which are then repressed. After the anti-FLAG-IP, which is mentioned above, 
Northern Blotting was performed. A probe against the endogenous miR-19b was used to 
detect the bound miRNA (Figure 7 A). A signal for the bound miR-19b could detected in Ago2 
WT and 555:61A mutant (Figure 7 A, lane 1-2), whereas in the 555:61E mutant, only weak 
signal of the bound miR-19b is visible (Figure 7 A, lane 3). This is consistent with the reduced 
binding of TNRC6 proteins. With a reduction in miRNA binding, 555:61E mutant could not be 
guided to the target and TNRC6 proteins could not be recruited. In conclusion, the silencing 
function of the phosphorylated 555:61 Ago2 protein is inhibited.  
To get a complete picture of the silencing activity of the 555:61 phosphorylation mutants, 
target RNA interaction was tested using qRT-PCR. After an anti-FLAG-IP of the Ago2 proteins, 
RNA was isolated and cDNA generated. The direct binding of the distinct mRNA of High 
Mobility group protein HMGI-C (HMGA2), which is a target of let-7, was checked. 555:61A 
mutant binds this mRNA like Ago2 WT (Figure 7 B). In contrast, 555:61E mutant had a very 
low affinity to the target, which is correspond with the impaired miRNA binding (Figure 7 B). 
Y529E mutant, which does not bind miRNAs132, and GFP served as negative controls and 
showed no mRNA interaction (Figure 7 B). A decreased miRNA binding of the hyper-
phosphorylated 555:61 Ago2 protein results in a low mRNA affinity.  
After checking for miRNA binding, these phosphorylation mutants were additionally tested 
for cleavage activity. After immunoprecipitation of the Ago2 proteins, they were incubated 
with a radiolabeled substrate RNA. In this in vitro cleavage assay, the endogenous miR-19b 
binds the perfect complementary substrate and cleaves it at a distinct position (indicated by 
the black bar in Figure 7 C). A signal for the cleavage product was detectable in the lane of 
555:61A mutant and is undistinguishable from WT (Figure 7 C, lane 1-2), contrary to 555:61E 
mutant, which showed only a very weak cleavage product (Figure 7 C, lane 3). The result of 
impaired cleavage activity of the 555:61E mutant was also shown by Dr. Judith Hauptmann154. 
Consistently with the assays described above, phosphorylation at positions 555:61 results in 
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an impaired miRNA binding and can therefore interact with mRNA or even cleave perfect 
complementary targets only in a reduced manner.  
Finally, the localization of Ago2 555:61A/E mutants was examined within the cell using 
immunofluorescence. P-bodies are sites in the cell where RNA metabolism takes place157 and 
it is known that Ago proteins localize to p-bodies as well24,94. With the anti-HA antibody, Ago2 
proteins were detected in green under confocal microscope. An antibody against U6 snRNA- 
associated Sm-like protein LSm4 (LSm4) detects the endogenous in red (Figure 7 D). LSm4 is 
a part of the cellular RNA decay machinery and served as a p-body marker. DAPI was used for 
nuclei staining (blue). While 555:61 un-phosphorylatable mutant showed a co-localization 
with LSm4 in p-bodies (Figure 7 D, upper panel), 555:61E mutant was not detectable in these 
structural elements (Figure 7 D, lower panel). In conclusion, the Ago2 555:61 phospho-
mimicking mutant is not located in p-bodies, indicating that hyper-phosphorylation at 
positions 555:61 affect localization within the cell and may also reduce silencing activity. This 
finding is consistent with the reduced binding of TNRC6 proteins (Figure 7 A), miRNAs 
(Figure 7 A), mRNAs (Figure 7 B) and the hindered silencing activity (Figure 6 D). 
However, in all these approaches the 555:61 non-phosphorylatable mutant behaves like WT 
(Figure 7). Since only mono-phosphorylated peptides were measured in this peptide and 
there were no phenotypes with single mutants in the tethering assay (Figure 6 D), this cluster 
was not characterized further, because effects of multiple phosphorylations could be artificial.  
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Figure 7 Functional analysis of the 555:61 phosphorylation cluster.  (A) Immunofluorescence of HeLa cells 
transfected with F/H-tagged Ago2 555:61 phosphorylation mutants. Ago2 constructs were detected via anti-HA 
antibody (green), the endogenous LSm4 is stained in red and serves as p-body marker. The nuclei are stained via 
DAPI (blue). (B) HEK 293T cells were transfected with F/H-tagged Ago2 constructs, immunopurified with anti-
FLAG antibodies, and separated on an SDS-PAGE or urea-gel and analyzed by either Western Blotting or Northern 
Blotting. Co-precipitated TNRC6 proteins were detected by pan-TNRC6-antnibody, clone 7A9. Ago2 proteins were 
detected by anti-HA antibody. For detection of the bound miRNAs, radioactively labeled probes against the 
endogenous miR-19b was used. (C) Cleavage activity of the 555:61 cluster mutants. F/H-Ago2 WT and mutants 
(GFP as negative control) were transfected in HEK 293T cells, immunopurified via anti-FLAG IP, incubated with a 
radioactively labeled substrate, which is perfect complementary to the endogenous miR-19b, followed by RNA 
isolation and separation on an 8 % sequencing gel. The black bar indicates the binding site of miR-19b. RNase T1 
digest is labeled with ‘T1’. (D) mRNA binding of Ago2 mutants. HeLa cells were transfected with F/H-Ago2 WT or 
555:61 A/E mutant. Ago2 Y529E or GFP were transfected as negative controls. After anti-FLAG-IP, RNA isolation 
and cDNA synthesis, the enrichment of HMGA2 was measured by qRT-PCR over input and normalized to WT. 
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2.1.3 Hyper-phosphorylation of the 824:34 cluster does not affect miRNA binding 
and localization 
 
Since there was no effect of the A or E mutant of 824:34 cluster in silencing activity, 
downstream steps were analyzed next. In a first approach, the miRNA and TNRC6 binding 
was checked. Therefore, the mutants were overexpressed in HEK 293T cells, 
immunoprecipitated by anti-FLAG antibodies from lysates, and either RNA isolated for 
Northern Blot analysis or interacting proteins eluted for Western Blot analysis. Both mutants, 
the phospho-mimicking and the phospho-lacking mutant, are able to bind TNRC6 proteins 
like WT suggesting that recruiting of additional factors for translational repression and mRNA 
degradation are not affected by phosphorylations at these positions (Figure 8 A, lane 2 and 
3). These mutants can also interact with miRNAs, like miR-19b, miR-21 and let-7a, as efficient 
as WT indicating that phosphorylations at 824:34 is not important for small RNA binding and 
also demonstrate that the mutants are not globally unfolded (Figure 8 A, lane 2 and 3).  
Next, the cellular localization of the 824:34A and E mutant was checked. Here, the Ago2 
proteins were stained with an antibody against its HA-tag in green, LSm4 functions as p-body 
marker are shown in red and DAPI was used for nuclei staining in blue. Both mutants co-
localize with LSm4 in p-bodies and are indistinguishable from WT (Figure 8 B). This result 
indicates that hyper-phosphorylation at the 824:34 cluster does not affect localization.  
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Figure 8 Functional analysis of the 824:34 phosphorylation cluster. (A) Immunofluorescence of HeLa cells 
transfected with F/H-tagged Ago2 WT and 824:34 phosphorylation mutants as described in Figure 7 A. (B) HEK 
293T cells were transfected with F/H-tagged Ago2 constructs, immunopurified with anti-FLAG antibodies, and 
separated on a SDS-PAGE or urea-gel and analyzed by either Western Blot or Northern Blot. Co-precipitated 
TNRC6 proteins were detected by pan-TNRC6-antnibody, clone 7A9, and Ago2 proteins were detected by anti-HA 
antibody. For detection of the bound miRNAs, radioactively labeled probes against the endogenous miR-19b, miR-
21 and let-7a were used. (C) Cleavage activity of the 824:34 cluster mutants as described in Figure 7 C. Western 
Blot was performed for control. 
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2.1.4 Phosphorylation at the 824:34 cluster is important for mRNA turnover 
 
To examine the endonucleolytic activity of the Ago2 824:34 phosphorylation mutants, in vitro 
cleavage assays were performed. Immunoprecipitated Ago2 proteins were incubated with a 
radioactively labeled substrate RNA containing a perfect complementary target site for the 
endogenous miR-19b (Figure 8 C, indicated by a black bar). The cleavage products were 
analyzed by RNA electrophoresis. Again, the phospho-mimicking mutant as well as the 
phospho-lacking mutants showed the same activity as WT in this endpoint measurements 
and are therefore catalytically active indicating that cluster phosphorylation does not 
generally impair activity (Figure 8 C, lane 4 and 5). GFP served as negative control (Figure 8 
C, lane 2).  
However, the in vitro cleavage assay might be artificial regarding target RNA binding since 
the substrate RNA is present in high excess and the products may accumulate over time. A 
difference in on/off-rates of mRNAs might be detected better at early time points where 
cleaved substrate is not yet accumulated. After immunoprecipitation, the protein-coupled 
beads were split into six cups and incubated with radioactively cap-labeled substrate, which 
is perfect complementary to the endogenous miR-19b. Cleavage activity were tested after 
different incubation times (1-30 min) with the substrate to elucidate potential differences in 
cleavage kinetics (Figure 9 A). Western Blot was performed as loading control for the in vitro 
cleavage assays (Figure 9 B). The cleavage assays were repeated in at least triplicates and the 
cleavage product was quantified to uncleaved target RNA. Indeed, the 824:34 phospho-
mimicking mutant showed reduced target cleavage at early timepoints in comparison to WT 
and the non-phosphorylatable mutant (Figure 9 A). Here, the cleavage kinetic curves of the 
Ago2 824:34E mutant shows slower target cleavage in comparison to WT or 824:34A mutant 
suggesting less efficient binding probably by higher off-rates of the hyper-phosphorylated 
Ago2 protein compared to WT Ago2 (Figure 9 C). 
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Figure 9 In-vitro cleavage kinetics of Ago2 824:34A/E mutants. (A) For cleavage kinetics of Ago2 WT and 
824:34 cluster mutants, cleavage assays were performed as described in Figure 7 C but with various reaction times 
from 1 to 30 min. After anti-FLAG IP, the beads with the bound proteins were split for the cleavage reactions. (B) 
For loading control, a part of the beads were eluted with Lämmli-sample buffer, loaded on a SDS-gel and analyzed 
by Western Blot with anti-HA antibody. (C) Quantification of relative cleavage kinetics of Ago2 WT and 824:34A/E 
mutants, (replicates ≥ 3, SEM). 
 
Lower binding affinity or lower dwelling time on the mRNA substrate could explain the 
observation of lower cleavage kinetics. Direct endogenous mRNA binding was therefore 
assessed in the next experiment using RNA-immunoprecipitation (RIP). Ago2 was 
overexpressed in HEK 293T cells, immunoprecipitated from lysates by their FLAG-tag, 
followed by RNA isolation. In addition to the IP samples, total RNA from inputs were isolated 
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to calculate the enrichment over input afterwards. This assay was performed in triplicates 
with WT, 824:34A and E mutant and as negative control the Ago2 Y529E mutant. This mutant 
is not able to bind miRNAs and should therefore not bind mRNAs132. Co-immunoprecipitated 
mRNAs were analyzed by microarray (Figure 10 A) and some specific targets were validated 
by qRT-PCR (Figure 10 B). 
 
 
Figure 10 Hyper-phosphorylation of the 824:34 cluster affects mRNA binding.  (A) Ago2 WT and 
phosphorylation mutants (Y529E serves as positive control) were overexpressed in HEK 293T cells, and 
immunoprecipitated via anti-FLAG-IP. RNA was isolated from three input samples and three biological replicates 
of each IP sample. The enriched mRNAs were analyzed by microarray, mutant vs. WT. The vertical line at 0 
represents the log2FC of zero compared to Ago2 WT. Western Blot was performed for control using anti-HA 
antibody. (B) For validation of the microarray analysis, RIP experiments were performed as before, cDNA was 
made and analyzed by qRT-PCR. Different targets (NFIC, ST6GALNAC6, SERBP1, F8A1, HAND1) were analyzed 
upon binging to Ago2 proteins. GFP and Ago2 Y529E served as negative controls. Relative enrichment over input 
was normalized to WT Ago2. Analysis was done in biological triplicates and calculated as mean (SEM). (C) Dual 
luciferase assay was performed on HMGA2-3’ UTR to observe the repression by overexpressed Ago2 constructs in 
MEF Ago2 -/- cells. (Replicates ≥ 3, SEM; p-values were calculated using a two-tailed Student’s test) Western Blot 
was performed as control. 
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In the microarray analysis depicted in Figure 10 A, the cumulative distribution of the log2-fold 
changes (log2FC) of Ago2 mutants in comparison to WT is shown. WT Ago2 associated 
mRNAs are represented as base line. On the left side of the zero line appeared weaker mRNA 
binding of the Ago2 mutant versus WT, the right side shows stronger binding. The negative 
control protein (Ago2 Y529E) bound only weakly to mRNAs, as it was expected since it is 
deficient of miRNA binding (Figure 10 A, light blue curve). The Ago2 824:34A mutant showed 
comparably or slightly stronger mRNA binding than the WT protein suggesting that without 
phosphorylation mRNA have a longer dwell time on Ago2 (Figure 10 A, green curve). 
Nevertheless, the Ago2 824:34 phospho-mimicking mutant appeared on the left side of the 
zero line. Hence, a strongly reduced mRNA binding was observed (Figure 10, dark blue curve). 
These results are consistent with the cleavage results and suggest that the hyper-
phosphorylation of the 824:34 cluster interfere with mRNA substrate binding.  
For validation of the direct mRNA interaction of Ago2 cluster phosphorylation mutants, the 
binding of five different targets (NFIC, ST6GALNAC6, SERBP1, F8A1, HAND1), which were 
identified in the microarray, were analyzed by qRT-PCR. After RIP, the enrichment of these 
targets was calculated over input and normalized to Ago2 WT. The 824:34 phospho-lacking 
mutant had a similar binding of mRNAs, while a reduced target binding could be detected 
with the 824:34E mutant, like the Ago2 Y529E control. Immunoprecipitated GFP served as 
negative control and did not bind any target above background (Figure 10 B). Consistently, 
the multiple phosphorylations at positions 824:34 affect mRNA binding in a negative way.  
Next, the effect of Ago2 824:34 cluster phosphorylation mutants on small RNA-guided gene 
silencing was tested in living cells by dual luciferase assay. For this assay, a luciferase reporter 
under control of the known let-7a target HMGA2-3’ UTR was transfected together with WT 
and mutant Ago2 proteins into Ago2 -/- mouse embryonic fibroblasts (MEFs) to investigate 
effects of only the transfected Ago2 versions without the endogenous background. Indeed, 
neither the phospho-mimicking cluster mutant nor the Ago2 Y529E negative control were 
able to repress the reporter luciferase, whereas the WT and the 824:34A mutant showed mild, 
but similar inhibition of reporter expression (Figure 10 C). In summary, these observations 
are pointing to a model, in which the hyper-phosphorylation of the residues 824:34 repels the 
negative charges of the target from Ago2.  
To figure out the step in miRNA-guided gene silencing, where Ago2 is hyper-phosphorylated 
at the 824:34 cluster, different mutants were used to quantify their phosphorylation level by 
quantitative mass spectrometry (selected reaction monitoring - SRM). These mutants are 
trapped in different steps of the gene silencing: The Ago2 Y529E132 mutant is not able to bind 
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miRNAs, should therefore not bind mRNA and does not localize in p-bodies. The 555:61A 
mutant is indistinguishable from WT Ago2 (Figure 7). The 555:61 phospho-mimicking 
mutant showed reduced miRNA and mRNA binding, no localization in p-bodies, it could not 
precipitate TNRC6 proteins and was not able to recruit downstream factors of the miRNA-
guided gene silencing machinery when tethered to the mRNA (Figure 6 D, Figure 7). And the 
last mutant, analyzed in this assay was Ago2 620/694W mutant. Here, the binding pockets 
for the tryptophans (Ws) of TNRC6 proteins were blocked by mutating A620 and leucine (L) 
at position 694 into Ws in Ago2. This mutant lacked TNRC6 binding and miRNA binding is 
reduced (Figure 11 A), did not localize in p-bodies (Figure 11 B) but was able to cleave target 
RNA158.  
 
 
Figure 11 Quantification of phosphorylation levels in various Ago2 mutants. (A) Western Blot Co-IP of 
FLAG/HA-tagged Ago2 WT and 620/694W mutant described as in Figure 7 B. (B) Localization of Ago2 620/694W. 
Procedure was the same as in Figure 7 A. (C) The phosphorylation sites S387 and the cluster phosphorylation 
824:34 were measured by quantitative mass spectrometry measurements (SRMs). For this, Ago2 mutants were 
overexpressed in HEK 293T cells, immunopurified by anti-FLAG IP, separated on an SDS-PAGE and stained with 
Coomassie Blue. The Ago2 bands were excised and prepared for mass spectrometry analysis. Isotope-labeled 
phosphorylated peptides were spiked into the tryptic in-gel digest. Bars represent the ratio phosphorylated:non-
phosphorylated peptide (p./n.p.). Phosphorylation of S387 serves as internal control. Measurements were 
performed in biological triplicates and calculated as mean (SEM). 
Results 
29 
 
To quantify the phosphorylation levels of these proteins, isotope-labeled and phosphorylated 
peptides were spiked into the sample. First, the Ago2 peptide from amino acid 385 to 395 
(SASFNTDPYVR) was spiked in, whereby S387 is phosphorylated or un-phosphorylated. 
Secondly, the peptide from position 815 to 837 (YHLVDKEHDSAEGSHTSGQSNGR) was used 
for quantification in an un-phosphorylated form, with a single phosphorylation on S824 and 
a four times phosphorylated version. For quantification, the ratios were calculated from 
phosphorylated/un-phosphorylated peptides in percent. Because the phosphorylation at 
position S387 was unaffected in each Ago2 mutant, this served as an internal control for the 
measurements (Figure 11 C, white bars). In Ago2 WT, a single phosphorylation level of S824 
could be measured at around 3.5 % (Figure 11 C, grey bars) and a multiple phosphorylation 
level at 1.5 % (Figure 11 C, black bars). Also, the 555:61A mutant showed similar single and 
quadruple phosphorylation levels. Whereas in the other mutants, which were trapped at 
various steps of the gene silencing process, a decreasing level of the 824:34 cluster 
phosphorylation could be detected (Figure 11 C). Altogether, this data suggests a 
phosphorylation event of Ago 824:34 cluster at a late stage of miRNA-guided gene silencing 
probably during Ago dissociation from the already silenced mRNA or recycling steps.  
 
2.1.5 Cluster phosphorylation is essential for ALG-1 function in vivo 
 
Together with Prof. Dr. Martin Simard (Laval University Cancer Research Centre, Quebec) and 
his group, we elucidated the function of the Ago2 824:34 cluster phosphorylation in vivo. This 
C-terminal cluster is also very conserved in ALG-1, the Ago2 ortholog in C. elegans159. The four 
serines are conserved through all four human Ago proteins and in ALG-1 isoform-a and -b 
(Figure 12 A). ALG-1 also contains a threonine in this cluster, but at a different position. In 
collaboration with Dr. Judith Hauptmann (University of Regensburg, Biochemistry I), we 
investigated phosphorylation of ALG1, using our biochemical strategies. Indeed, multiple 
phosphorylations were identified in this region from 988 to 998 (Figure 12 B).  
Next, Simard’s group performed a transgenic rescue assay in an alg-1 null allele strain alg-1 
(gk214) (alg-1 (0)) and expressed either WT alg-1 gene or mutants. Here, on the one hand 
single mutations of the position S992 (corresponding to S828 in human Ago2, indicated by a 
box in Figure 12 A) in phospho-mimicking (E) or phospho-lacking (A) were generated. On the 
other hand, complete cluster mutations, where the four serines were mutated into A or all 
potential phosphorylation sites were mutated into E (5A/4E), were used. For this rescue 
approach, they looked at the alae structure of the worms. Alae is a cuticular structure that 
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needs a precise developmental program, which is controlled by miRNAs160. They observed a 
strong phenotype in the alae structure of the worms expressing the 5A mutant and also the 
single S992A mutant (Figure 12 C). These worms showed no rescue of the alg-1 (0) resulting 
gapped alae structures or not even alae formation. However, the AGL-1 WT and the 4E/S992E 
expressing worms were able to rescue the alae phenotype and had complete alae structures160 
(Figure 12 C).  
 
Figure 12 C-terminal phosphorylation cluster is conserved in ALG-1 of C. elegans. (A) Alignment of all four 
human Ago proteins and C. elegans ALG-1 isoform-a and -b using Clustal Omega. (Q9UL18, Q9UKV8, Q9H9G7, 
Q9HCK5, G5EGR6, G5EES3) (B) Representative CID spectrum of a triple phosphorylated ALG-1 peptide of C. 
elegans (YHLVDREHDSGEGpSQPpSGpTSEDTTLSNMAR). This was generated from a LC-UHR-QTOF analysis. The 
phosphorylations were detected at position S992, S995 and T997 according to Mascot. Monoisotopic mass: 
3,515.34 Da, Mascot ion score: 53, expectation value: 4.8e-006, D mass: 0.01 Da. (C) Overexpressed non-
phosphorylatable ALG-1 mutant (988:98A, 5A; S992A) worms were not able to rescue the alae structure in an alg-
1 (0) background. Phospho-mimicking ALG-1 animals (988:98E, 4E; S992E) rescued the alae formation defects of 
alg-1 depleted worms. The number of monitored animals is indicated as ‘n’160. 
 
Furthermore, our collaborators generated phospho-mimicking and non-phosphorylatable 
ALG-1 S992 mutant worms by CRISPR-based genome editing to avoid artefacts caused by 
overexpression. With this model system, they could show developmental defects with the 
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S992A and E mutant but a stronger phenotype with the A mutant. For example, almost all 
S992A mutant worms died after the transition from larval to adult stage, bursting from the 
vulva160. They also observed an excess number of seam cells of the mutant and alg-1 (0) 
worms in comparison to the 16 seam cells in WT ALG-1 worms160. Moreover, the group of 
Martin Simard monitored a strong de-repression by using transgenic animals expressing a 
GFP reporter under control of a lin-41 3’UTR. This 3’UTR is regulated by let-7 miRNA in the 
transition from larval to adult stage and should be repressed in WT worms. But the ALG-1 
S992A and E mutant worms were not able to repress the reporter and so a GFP signal was 
still visible160. These assays indicate that the cluster phosphorylation of the 988:98 is essential 
for ALG-1 function in vivo. 
 
2.1.6 Modifying enzymes 
 
In summary, all the results described above point towards an essential role of the Ago 824:34 
phosphorylation. It is conceivable that the de-phosphorylation could occur as well, and a 
phosphorylation-de-phosphorylation cycle might regulate Ago function. Kinases and 
phosphatases that are involved in phosphorylation and de-phosphorylation of these sites 
remain unknown. Since a single site mutation (S992) results in a strong phenotype in C. 
elegans, it is unclear if the corresponding site in human Ago2, S828, is more important than 
the other residues of the 824:34 cluster.  
To gain new insights regarding interacting kinases and phosphatases, and thus in the 
regulation of Ago proteins, mass spectrometry data was analyzed to find interacting partners 
of Ago proteins. First, published data from Dr. Anne Frohn was scoured to identify relevant 
kinases and phosphatases161. Here, a number of enzymes were found, but the subunits of one 
phosphatase were exceptional: Protein phosphatase 6 (PP6) and its subunits. This 
phosphatase is a heterotrimeric complex composed of a catalytic subunit PPP6C, a SAPS 
domain-containing subunit (PP6R1-3) and an ankyrin repeat-domain containing regulatory 
subunit (ANKRD28, 44, 52)162,163. In the mass spectrometry data of Dr. Anne Frohn SAPS3 or 
PP6R3, ANKRD28 and PPP6C could be identified as potential interacting partners of Ago2161.  
To test whether these proteins are indeed involved in Ago de-phosphorylation, the single 
subunits were knocked down via sipools (siTools, Munich). For this experiment, siPools 
against PPP6C, PP6R1-3 and ANKRD28, 44, 52, and control sipools were transfected into HEK 
293T cells and harvested 48 h after knock down. Subsequently, immunoprecipitation of 
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endogenous Ago2 was performed, followed by a sample preparation for quantitative mass 
spectrometry with the focus on the phosphorylation cluster 824:34 and the phosphorylation 
S387 as internal standard for phosphorylation level and comparable amounts of 
phosphorylated Ago (Figure 13).  
 
 
Figure 13 Phosphorylation levels of the 824:34 cluster and S387 in Ago2.  The phosphorylation sites S387 
and the cluster phosphorylation 824:34 were measured by quantitative mass spectrometry measurements 
(SRMs). For this, the single subunits of PP6 were knocked down for 48 h in HEK 293T cells, immunopurified by 
anti-Ago2 IP, separated on a SDS-PAGE and stained with Coomassie Blue. Further procedure was performed as 
described as in Figure 11. The dashed lines represent the phosphorylation levels of the control knock down.  
 
In the control knock down, a phosphorylation level at approximately 6 % of the total Ago2 
protein level was detected when a single S824 phosphorylated peptide was used as reference. 
About 1 % is phosphorylated at four residues when the four times phosphorylated peptide 
was spiked in as reference. Upon knocking down the factors of PP6, an increased single 
phosphorylation level could be measured. Especially upon knock down of ANKRD52, the 
phosphorylation level of S824 raised to around 20 % (Figure 13). Additionally, an immense 
increase (around 10 %) of the quadruple phosphorylated 824:34 cluster was observed when 
ANRKD52 was knocked down (Figure 13). The knock down of PP6R1, PP6R3, ANKRD28 and 
ANKRD44 showed a slight increased level of the single phosphorylated peptide at position 
S824 at a level of approximately 0.5-1.5 % (Figure 13). The level of the four times 
phosphorylated peptides after the knock down of PP6R1, PP6R3, ANKRD28 and AKNRD44 
did not change in comparison to the control knock down (Figure 13). Whereas the knock 
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down of PPP6C results in phosphorylation level of position S824 at approximately 12 % and 
a multiple phosphorylated peptide 824:34 at around 2 % (Figure 13). Also, an increase in the 
levels of single phosphorylation (approx. 14 %) and quadruple phosphorylation (approx. 3 
%) of the 824:34 peptide was measured in the knock down of PP6R2 (Figure 13). The 
phosphorylation level of S387 is stable in every sample of this experiment and appears at 
around 2 % (Figure 13). In conclusion, a phosphatase complex presumably composed of 
PPP6C-PP6R2-ANKRD52 acts on Ago de-phosphorylation of the 824:34 cluster. 
According to this experiment, the most important factor for de-phosphorylation of the 824:34 
cluster seems to be ANKRD52 of PP6 holoenzyme. The group of Prof. Dr. Joshua Mendell also 
confirmed this finding. His group identified PPP6C in combination with ANKRD52 as the 
phosphatase and casein kinase 1α (CSK1A1/CK1) as responsible kinase for the 824:34 cluster 
in a genome-wide CRISPR screen164. 
The CSK1A1 as a potential kinase needs an initial phosphorylation to bind and phosphorylate 
its substrates. The next aim was the identification of the priming site. Therefore, mutants 
were generated, and their phosphorylation pattern were analyzed. These five mutants have 
their potential phosphorylation sites mutated to single alanines at position 824, 828, 830, 
831, and 834. The single-A mutants were then overexpressed in HEK 293T cells, 
immunopurified via their FLAG-tag, separated on an SDS-PAGE and prepared for mass 
spectrometry to assess the phosphorylation pattern of each mutant.  
 
 
Figure 14 Phosphorylation pattern of different alanine-mutants of the 824:34 cluster. Ago2 824:34 single 
alanine mutants were generated, overexpressed in HEK 293T cells, immunopurified, separated on an SDS-PAGE 
and analyzed via mass spectrometry. The phosphorylation pattern of at least three biological replicates of each 
mutant were measured. Green As mark the mutated serines or threonine. Detected phosphorylated sites are 
depicted in red with a prefixed ‘p’. CK1 is short for CSK1A1. The arrows show phosphorylation events after initial 
phosphorylation.  
 
Results 
 
Interestingly, the mutation of S824A had no effect on the subsequent phosphorylated sites 
(Figure 14 (1)). The mutation of the S828A affected the subsequent sites. The residues 830, 
831 and 834 showed no phosphorylation, whereas phosphorylation could be detected at S824 
(Figure 14 (2)). With the mutation of T830A and S834A, every combination of 
phosphorylations were measured (Figure 14 (3,5)). In contrast, after mutation of S831A, only 
the residues before were measured to be phosphorylated, not S834 (Figure 14 (4)). These 
findings lead to the assumption that S828 is a very important site for the hyper-
phosphorylation and could thus be the priming site. After an initial phosphorylation of S828, 
CSK1A1 phosphorylates the S831, followed by S834 (Figure 14). This is result is consistent 
with the data obtained in C. elegans. When mutating S992 into A, which is corresponding to 
S828 in human Ago2, the worms showed a strong phenotype (Figure 12 C). This kinase needs 
an initial phosphorylation and subsequently phosphorylates every third potential residue. 
Additionally, the group of Prof. Dr. Joshua Mendell performed in vitro kinase assays with 
CSNK1A1164 and the results correlated with the outcome of the described experiment (Figure 
14).  
In summary, the protein phosphatase 6, particularly the complex PPP6C-PP6R2-ANKRD52, 
might be responsible for de-phosphorylation of the 824:34 cluster. The de-phosphorylation 
may allow Ago to be recycled and go into another round of repression. Furthermore, 
CSNK1A1 was identified to be involved in phosphorylation of 824:34 cluster, but this kinase 
needs an initial phosphorylation to be enzymatically active. Here, the phosphorylation of 
S828 was identified to be very important for hyper-phosphorylation of this cluster and thus 
may be the priming site for the initial phosphorylation. Other kinases, which are needed i.e. 
for the priming phosphorylation remain still unknown and will be exciting future research 
subjects. 
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2.2 Ago2 mutations result in human neurodevelopmental disorders 
 
In the second part of my thesis, I have biochemically investigated Ago2 mutations found in 
disease. Ago proteins are known to be key factors in small RNA-guided gene silencing. The 
group of Prof. Dr. Hans-Jürgen Kreienkamp and Dr. Davor Lessel from the Medical Center 
Hamburg-Eppendorf discovered Ago2 mutations in human neurodevelopmental disorders. In 
collaboration, functional effects of these mutations were investigated in biochemical assays. 
 
2.2.1 Ago2 mutations and neurodevelopmental disorders 
 
It is known that mis-regulated Ago expression levels can cause in various diseases, like 
Huntington’s disease152, or cancer143,144,146,148,149. The Kreienkamp/Lessel lab sequenced the 
genome of different patients. These children showed a similar phenotype: they were mentally 
retarded and started to talk and walk very late. But it was very interesting that from the 
exome sequencing results, only heterozygous mutations in Ago2 could be found. They 
identified eight different point mutations and one deletion of an amino acid: phenylalanine 
(F)182 deletion (del), leucine (L) 192 into proline (P), glycine (G) at the position 201 mutated 
into cysteine (C), histidine (H) 203 into glutamine (Q), methionine (M) 364 into T, A367 into 
P, G733 to arginine (R), and S760 mutated into R (Figure 15 A, red bars). The mutations 
F182del, L192P, G201C and H203Q are located in the linker 1 (L1) regions, the mutations 
M364T and A367P are positioned in the linker 2 (L2) region and the mutations G733R and 
S760R are in the PIWI domain (Figure 15 A). Interestingly, all these mutations independently 
resulted in a similar phenotype of the children. In addition, the mutation L192P was found in 
two independent patients, one from the Netherlands and one from Seattle, showing the same 
phenotype.  
In addition, G201 was found once mutated to C and in another patient it was mutated into 
valine (V). Twins were sequenced with the same phenotype described before with a mutation 
at C751Y, which is positioned in the PIWI domain (Figure 15 A). The mutation G201V and 
C751Y were detected at a later stage and could not be included in this work. Altogether, 
heterozygous mutations in Ago2 appear to result in a neurodevelopmental phenotype in 
patients, although a second un-mutated copy is present. 
 
Results 
 
2.2.2 Functional analysis of the disease related mutations in Ago2 
 
To analyze effects of these mutations on Ago function, the mutants described above were 
generated and tested in various assays.  
 
 
Figure 15 Functional analysis of Ago2 disease related mutants.  (A) Schematic depiction of Ago2 and its 
domain structure. Red bars represent mutations that were found in patients. (B) Co-immunoprecipitation of Dicer. 
F/H-tagged Ago2 WT and mutants were overexpressed in HEK 293T cells, purified via anti-FLAG antibody, 
separated on an SDS-PAGE and analyzed via Western Blotting. (C) The procedure was described in (B), but the 
membrane was incubated with anti-TNRC6 antibody. After the IP, the samples were split on the one hand for 
Western Blot detection, on the other hand for RNA isolations followed by Northern Blotting. The Northern Blot 
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was incubated with a radiolabeled probe against endogenous miR-19b. (D) Ago2 cleavage assay. The experiment 
was performed as described in Figure 7 C. (E) Dual luciferase assay to analyze the silencing ability of Ago2 mutants. 
Ago2 WT, mutants and empty vector were co-transfected with a plasmid encoding for RNL as control and FF under 
control of HMGA2-3’UTR in HeLa cells. For calculation, the ratio FF/RNL signals were normalized to empty vector 
(EV). 
 
First, a co-immunoprecipitation was performed to see the interaction of Ago2 mutants with 
TNRC6 proteins and/or Dicer. For this, Ago2 WT and mutants were overexpressed in HEK 
293T cells, immunopurified via their FLAG-tag, and analyzed by SDS-PAGE. After Western 
Blotting, the membrane was incubated with anti-HA antibody for Ago2 proteins and either 
anti-TNRC6 or anti-Dicer antibody. Every tested mutant was able to interact with Dicer 
(Figure 15 B).  
In addition, all Ago2 mutants showed an interaction with TNRC6 proteins (Figure 15 C, lane 
1-5 and 7-11), except for mutant G733R. With this mutant, no or reduced signal of TNRC6 
proteins could be detected (Figure 15 C, lane 6). In addition to the bound proteins, RNA was 
isolated after the anti-FLAG IP and the interaction with miR-19b was analyzed. Here, only a 
weak signal of bound miR-19b could be detected with the mutant G733R (Figure 15 C, lane 
6). All the other Ago2 mutants showed a signal for miR-19b comparable to Ago2 WT (Figure 
15 C, lane 1-5 and 7-11). These results indicate that Ago2 mutants are loaded with miRNAs 
correctly by Dicer (Figure 15 B) but the miRNA binding is reduced with mutation G733R 
(Figure 15 C, lane 3, 8). 
After confirming miRNA and TNRC6 binding except for G733R, the next analysis was Ago2 
cleavage activity. Therefore, Ago2 WT and mutants were expressed in HEK 293T cells, 
immunopurified, and incubated with a radioactively labelled target substrate, which is perfect 
complementary to the endogenous miR-19b. Afterwards, RNA was isolated, and separated on 
an urea sequencing gel. An Ago2 WT-comparable cleavage activity could be observed for the 
Ago2 mutants (Figure 15 D, lane 2, 5-8, 10), except for the G733R mutation protein (Figure 
15 D, lane 9). Since this mutant showed a reduced miRNA binding, it was not surprising to see 
a lower cleavage activity. The mutants F182del and L192P showed reduced cleavage products 
but the in the Western Blot these two proteins appeared to be lower expressed (Figure 15 D, 
lane 3, 4). That is probably the reason for the decreased cleavage activity. GFP was used as 
negative control (Figure 15 D, lane 11).  
In a next approach, the silencing ability of the mutants was tested using dual luciferase assay. 
Therefore, Ago2 constructs were expressed in HeLa cells together with a dual luciferase 
reporter. This reporter expresses Renilla luciferase mRNA for control and Firefly luciferase 
mRNA under control of HMGA2 3’UTR, which is a known target for let-7. After cell lysis, the 
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signals were read out by an illuminometer. The relative FF/RNL ratios were calculated and 
normalized to the empty vector. For negative control, the Ago2 Y529E mutant, which does not 
bind miRNAs132, was tested and this mutant showed no repression almost like the empty 
vector (Figure 15, E). The G733R mutant behaved like the negative control and a strong de-
repression could be observed (Figure 15, E). This result is consistent with the reduced miRNA 
binding and TNRC6 interaction of the G733R mutation. In contrast, all the other mutants 
showed a repression of the firefly mRNA in the WT range suggesting that these mutations do 
not affect silencing activity of Ago proteins (Figure 15, E).  
For complete functional analysis, the localization of the Ago2 mutants found in patients were 
examined. For this, Ago2 constructs were overexpressed in HeLa cells, seeded on cover slips, 
fixed with paraformaldehyde and incubated with anti-LSm4 (red), which served as p-body 
marker, and anti-HA (green) antibody. The nuclei were stained with DAPI (blue). The 
localization of the Ago2 mutants gave the same picture as the assays mentioned above: all 
Ago2 mutants nicely co-localized with the LSm4 in p-bodies, except for the G733R mutant. 
This one was only found in the cytoplasm but not in dot like structures (Figure 16). Taken 
together, all tested mutants showed similar behavior to Ago2 WT in the described functional 
assays, except for the G733R mutant. 
 
 
 
 
 
 
 
 
 
 
Figure 16 Immunofluorescence of Ago2 disease related mutants. Ago2 mutants were overexpressed in HeLa 
cells, fixed on cover slips and proteins were detected via specific antibodies: anti-HA for Ago2 proteins (green), 
anti-LSm4 as p-body marker (red) and DAPI for nuclei staining (blue). All mutants were shown separately in 
immunofluorescence from top to bottom starting with WT.  
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2.2.3 Mutations affect mRNA binding 
 
With the background of the methods, described in section 2.1.4, the mutants were analyzed 
concerning their phosphorylation level at the 824:34 cluster, which is near the miRNA-mRNA 
position. If this is hyper-phosphorylated, the negative charges of the phosphates can lead to 
the repulsion of bound and negatively charged mRNA. This results in the loss of mRNA (Figure 
10, dark blue curve, 824:34E). Without multiple phosphorylations at this peptide, mRNAs can 
be bound longer or stronger to this Ago protein (shown in Figure 10, green curve, 824:34A). 
With this knowledge, a link from the phosphorylation level to bound mRNA within a strong 
phenotype could be established.  
To measure the relative phosphorylation levels of the 824:34 cluster, Ago2 mutants, which 
were found in patients, were overexpressed in HEK 293T cells, immunopurified, analyzed by 
SDS-PAGE and prepared for mass spectrometry. For relative quantification, 
unphosphorylated and phosphorylated heavy labelled peptides were spiked into the samples 
before trypsin digestion (as described in Figure 11). Phosphorylation of S387 served as 
internal control for the measurements and showed equal levels in each mutant and WT 
(Figure 17 A, light grey bars). The single phosphorylation S824 was measured in Ago2 WT at 
levels of approximately 3.5 % of total Ago2, the patient mutants showed single 
phosphorylation levels from 1-3 % (Figure 17 A, grey bars). Almost no single phosphorylation 
was measured in the G733R mutant. Looking at the four times phosphorylated version of the 
824:34 peptide, a phosphorylation level of around 2 % was measured in the Ago2 WT sample. 
In all other Ago2 mutants, a heavily reduced level of quadruple phosphorylated peptides 
could be observed, except for the H203Q mutant. Here, a level up to 3.5 % was measured but 
with a high error bar. The other mutants showed a decrease of hyper-phosphorylation, which 
leads to the suggestion that the mRNA might be bound stronger to the Ago proteins because 
of generally less Ago2 S824:34 cluster phosphorylation (Figure 17 A, black bars).  
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Figure 17 mRNA interaction of Ago2 disease related mutations.  (A) Relative quantification of the 
phosphorylation level. After overexpression of Ago2 mutants in HEK 293T cells, phosphorylation of S387 (light 
grey bars), S824 (grey bars) and four times phosphorylated 824:34 (black bars) were measured and quantified 
via SRM. Phosphorylation of S387 serves as internal control. Measurements were performed in biological 
triplicates and calculated as mean (SEM). (B) RIP experiments were performed as described in Figure 10 A, cDNA 
was generated and analyzed by qRT-PCR. Different targets (NFIC, ST6GALNAC6, F8A1, HAND1) were analyzed 
upon binging to Ago2 mutants. GFP and Ago2 Y529E served as negative control. Relative enrichment over input 
was normalized to WT Ago2. Analysis was done in biological triplicates abs calculated as mean (SEM). 
 
To validate this mRNA binding-hypothesis, RIP experiments were performed and analyzed 
using qRT-PCR. Therefore, Ago2 WT and mutants were overexpressed in HEK 293T cells, 
immunopurified with their FLAG-tag, extensively washed, RNA was isolated, and cDNA was 
generated. Using qRT-PCR, four targets were tested for binding to Ago2 mutants: F8A1, NFIC, 
HAND1 and HOXC8 (Figure 17 B). For negative control, Ago2 Y529E mutant was used. The 
enrichment of targets was calculated over input RNA and normalized to Ago2 WT binding. All 
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mutants showed more target enrichment over input in comparison to WT, except of Ago2 
G733R. The enrichment of targets reached from 1.5- up to 3-fold compared to Ago2 WT. As a 
control, the Ago2 mutant E186K was used. This mutation can be found in normal people 
without any phenotype. In the qRT-PCR analysis, the Ago2 E186K mutant showed similar 
mRNA binding to Ago2 WT. Both, the enrichment of targets and hypo-phosphorylation of the 
824:34 cluster strengthen the hypothesis that all Ago2 mutants related to the disease show 
stronger and/or longer interaction with targets, except of Ago2 G733R. This mutant showed 
weak binding to TNRC6 proteins, miRNA and mRNAs, did not localize in p-bodies. Moreover, 
it is not phosphorylated on the 824:34 cluster and had less cleavage activity. This mutant 
seems to be catalytically dead but nevertheless it results in the same neurodevelopmental 
disease as the other mutations.  
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3 Discussion 
 
3.1 Endogenous phosphorylation sites of Ago proteins  
 
In this work, a systematic and unbiased mass spectrometry analysis of endogenous Ago 
phosphorylation sites from different species was performed. Different purification strategies 
were used to isolate endogenous Ago proteins of human, mouse, rat, zebrafish and C. elegans. 
Subsequently, specific phosphorylation sites were functionally characterized by generating 
phosphor-lacking and phospho-mimicking mutants, followed by experimental analysis using 
a large panel of different approaches and assays. 
 
3.1.1 Conservation and positioning of phosphorylation in Ago protein 
 
Many of the measured phosphorylation sites are conserved between the four human Ago 
proteins. Furthermore, there are also phosphorylation sites, which are conserved in various 
species. The well-characterized phosphorylation at S387132,135–137,139 is conserved in mouse 
and rat. To avoid technical artifacts, measurements were performed in triplicates and only 
overlapping phosphorylation sites were considered as ‘real’ phosphorylations (Figure 5 A). 
Two phosphorylated peptides containing multiple phosphorylatable residues appeared to be 
very conserved: the first phosphorylations were seen between T555 and S561. This area is 
located around the binding pocket of the target mRNA that is close to the first miRNA 
nucleotide (Figure 18 A). This nucleotide is tightly bound to the Ago MID domain and is not 
involved in the target interactions73,165. Here, only single phosphorylations were measured 
(Figure 6 B). The second phosphorylations, which appear in a cluster, are positioned between 
S824 to S834. These residues are located on an exposed and most likely flexible loop, which 
is not resolved in the human Ago2 crystal structure71,73 (Figure 18 B). The end residues of this 
loop, which are resolved in the crystal structure, are E821 and G836. Nevertheless, this loop 
is resolved in the crystal structure of Ago protein QDE-2 protein of Neurospora crassa, where 
it is three residues shorter than in human Ago2166 (Figure 18 C). However, an alignment with 
both structures reveals that the loop could potentially reach the bound mRNA:miRNA duplex 
due to this structural flexibility (Figure 18 C). Therefore, it is likely that the multiple cluster 
phosphorylations could affect RNA binding caused by repulsion of negative charges on the 
RNA backbone and the phosphorylated residues found in mass spectrometry. This cluster 
Discussion 
 
contained five phosphorylatable residues and tryptic peptides found in mass spectrometric 
analysis were up to four times phosphorylated (Figure 6 C). The reason, why 
phosphorylations could not be measured in our mass spectrometric analysis might be due to 
technical issues, which are discussed in the following chapter. However, the 824:34 potential 
phosphorylation sites are conserved in dmAGO1, which is involved in miRNA-guided 
repression, but not in the dmAGO2, which carries out siRNA-mediated target 
silencing164,167,168. Thus, it is likely that these phosphorylations are only conserved in Ago 
proteins, which perform miRNA-mediated repression. It is tempting to speculate that cluster 
phosphorylation could even be a predictor of a miRNA-Ago protein in so far unknown species. 
All Ago proteins that are involved in miRNA-guided repression that we have examined so far, 
appear to utilize this mechanism for optimized target release. 
 
3.1.1.1 Technical challenges 
 
In general, phosphorylations are difficult to measure in mass spectrometry169–171. First, the 
ionization efficiency is poor. Second, phosphorylated peptides have a specific fragmentation 
behavior. This might be due to their negative charges, especially when the peptides are 
multiply phosphorylated172. Moreover, it can be very challenging to assign a phosphorylation 
to a specific amino acid in case the peptide contains more potentially phosphorylatable 
residues and the fragment ion spectra do not provide sufficient sequence information173. 
Additionally, redistributions of phosphates to other potentially phosphorylatable residues 
can happen in the gas phase. These events make the positioning of the phosphates to specific 
residues very difficult174. In many cases less than 5 % of a protein population is 
phosphorylated. Thus, it is very difficult to get enough endogenous protein material to 
reliably measure challenging or rare phosphorylation events. In addition, de-phosphorylation 
can occur during extract preparation. Therefore, it is necessary to include phosphatase-
inhibitors while lysate preparation to block phosphatases. Furthermore, tryptic digestions 
are frequently not complete and this causes missed cleavages175–177. In consequence, some 
peptides are longer than the fully digested ones and can therefore not be included in relative 
quantification methods like SRM. In this method, heavy labeled peptides with a defined 
length, with or without phosphorylations, are spiked into the sample and are used for relative 
quantification175–179.  
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Figure 18 Localization of phosphorylation sites in Ago2.  (A) Localization of the phosphorylation sites 555-
561. These sites are shown in red, based on the model 4W5O71. (B) Position of the unresolved loop starting from 
E821 to G836. The miRNA is shown in orange, a part of the mRNA is indicated in green71. (C) Overlay of similar 
structures of Neurospora crassa Ago protein QDE-2 (pink), based on the model 2YHA166 and human Ago2 (grey). 
The corresponding loop of human Ago2 is three residues longer than the loop of QDE-2. 
 
3.1.1.2 Examples for biological functions of cluster phosphorylations 
 
It is known that phosphorylations at serines or threonines tend to appear in clusters in 
eukaryotes180. Various clustered phosphorylations were found with several biological 
functions181. One example are the phosphorylation repeats of the C-terminal domain of RNA 
polymerase II. The phosphorylations are known to function as specific binding platforms and 
the pattern changes during transcription allowing for specific binding of different 
transcription and mRNA processing factors during distinct steps of the transcription cycle182. 
Another example of multiple phosphorylations is found in the Sic1 protein of Saccharomyces 
cerevisiae. This protein is a cyclin-dependent kinase inhibitor and it has been shown that 
multiple phosphorylation sites contribute to ubiquitination in vitro and degradation in vivo183. 
Furthermore, for an efficient substrate recognition by Cdc4, a component of the SCF E3 
ubiquitin-protein ligase complex, Sic1 requires at least phosphorylations at six out of nine 
potential phosphorylated residues184,185. Cluster or multiple phosphorylations could be more 
general motifs or mechanisms for protein-protein interactions. Moreover, multiple 
phosphorylations can disturb membrane association or DNA/RNA binding due to repulsion 
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of negative charges160,164,186,187. Another example for multiple phosphorylated proteins are 
serine and arginine-rich (SR)-proteins. These proteins are RNA-binding proteins and known 
as constitutive and alternative splicing regulators. Phosphorylation is necessary for nuclear 
import of SR-proteins188 or can allow the recruitment of these proteins from nuclear speckles 
to RNA during splicing189. Phosphorylations are also required for spliceosome assembly and 
the dynamic switch of the phosphorylation level of SR-proteins modulate splicing190–193. Ago 
proteins may also be regulated by a dynamic switch between hypo- and hyper-
phosphorylated state.  
 
3.1.2 Functional analysis of Ago2 cluster phosphorylations 
 
To test the function of the phosphorylation cluster, the phosphorylated serines and 
threonines were mutated into alanine, a non-phosphorylatable mutant and into glutamate, 
which served as phospho-mimicking mutant because glutamate contributes a negative charge 
like those of phosphorylated side chains. Single and cluster mutants were generated and first 
tested on their function to repress targets when artificially tethered to the mRNA. Since all 
single, as well as 824:34A/E and 555:61A mutants could repress the target like WT, it is likely 
that the mutants are folded correctly (Figure 6 D). Additionally, these data also indicate a 
function of these phosphorylations upstream of deadenylation and translational repression, 
since downstream silencing is not affected when tethered. On the contrary, the target 
repression of 555:61E mutant is strongly impaired when tethered (Figure 6 D). Furthermore, 
this mutant does not localize in p-bodies, shows reduced binding of TNRC6 proteins, mRNA 
binding is negatively affected and also the cleavage activity is compromised (Figure 7). All 
this suggests a potentially incorrect folding of the 555:61E mutant. Since only single 
phosphorylations were measured in mass spectrometry originating from the 555:61 region 
and the single mutants were indistinguishable from Ago2 WT, we concluded that this region 
does not contain a simultaneously phosphorylation cluster and discontinued its further 
examination (Figure 6 B).  
Our mass spectrometry data regarding the 824:34 cluster was different. Here, up to 
quadruple phosphorylations were measured on single peptides from this region (Figure 6 C). 
The cluster mutants, all five phosphorylatable residues on this peptide mutated into either A 
or E, were tested in various assays. Both mutants showed WT behavior in subcellular 
localization, miRNA and TNRC6 binding. In addition, cleavage activity was not affected by 
phosphorylations after 1.5 h of reaction time (Figure 8). This points towards a generally 
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functional catalytical activity of both mutants. Since cleavage assays may have reached a 
plateau after 1.5 h (end-point measurements) with a high excess of substrate, products may 
accumulate during reaction to similar amounts although mRNA affinities might be different. 
These difficulties can be overcome by kinetic measurements in a much shorter time window. 
Indeed, reduced cleavage activity at early time points of the 824:34E mutant were monitored 
compared to WT and 824:34A mutant (Figure 9). This might be due to lower target RNA 
affinity or higher off-rate of the phospho-mimicking mutant. To test direct mRNA binding, 
RNA-immunoprecipitations were performed and analyzed via micro array. The Ago2 Y529E 
mutant served as a negative control as its miRNA binding is impaired and therefore no mRNAs 
are bound to it132. In fact, a strongly reduced mRNA binding of this mutant was detected in 
comparison to Ago2 WT. In addition, an impaired mRNA binding could be detected with the 
824:34E mutant, which mimics a hyper-phosphorylated state. However, the 824:34A mutant 
bound mRNAs similar to WT or even stronger (Figure 10 A). Consistently, also in qRT-PCR 
measurements, the 824:34E mutant demonstrate reduced target RNA binding (Figure 10 B). 
In living cells, the 824:34 phospho-mimicking mutant was not able to repress the reporter 
(Figure 10 C). The rather mild effects observed in Figure 10 C might be based on the rather 
low transfection efficiency. 
For elucidation in which step of gene silencing phosphorylation at the loop between the 
residues E821 and G836 occurs, different mutants were used and analyzed regarding their 
phosphorylation at the 824:34 cluster. No cluster phosphorylation was detected in Ago2 
mutant 620/694W, which is impaired in TNRC6 protein binding due to mutations in of the 
binding sites. That also indicates that only Ago, which can interact with TNRC6 proteins, is 
subsequently hyper-phosphorylated. In addition, reduced phosphorylation was measured in 
the Ago2 Y529E mutant, which cannot bind miRNAs132, and 555:61E, which showed impaired 
mRNA binding. In contrast, WT and the 555:61A mutant, which is similar to WT in all utilized 
assays, contained single and quadruple phosphorylations at the 824:34 cluster (Figure 11 C, 
grey and black bars). All these quantifications were performed by quantitative mass 
spectrometry (SRM). Phosphorylation at position S387 served as control and did not differ in 
any mutants mentioned above, indicating that our results are not due to global 
phosphorylation artifacts (Figure 11 C, white bars). Notably, all mutants, which are trapped 
in different stages of gene silencing, showed impaired phosphorylations at the 824:34 cluster. 
In summary, this suggests that the Ago2 824:34 cluster is hyper-phosphorylated at later 
stages of small RNA-guided gene silencing. Probably, the phosphorylation event occurs during 
or for dissociation from silenced mRNPs or recycling steps. This model, however, needs to be 
validated in more detail. 
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3.1.3 Cluster phosphorylation is essential for ALG-1 function in-vivo 
 
To assess the physiological relevance of the 824:34 cluster phosphorylation, Prof. Dr. Martin 
Simard (Quebec, Canada) and his group worked with C. elegans as model organism. Here, 
developmental processes and defects can be studied easily. Mutating just one residue, 
probably the most important residue in this cluster, had strong effects160. In summary, the 
S992 is a very important site in this cluster and its ability to get phosphorylated plays a big 
role in development. 
 
3.1.4 Modifying enzymes acting on the Ago2 824:34 cluster 
 
Phosphorylations are a general mechanism for regulating Ago protein function55,132–139. The 
key players of this kind of regulation are kinases and phosphatases, which place or remove 
phosphorylation marks. In the particular case of the Ago2 824:34 cluster phosphorylation, 
the Protein Phosphatase 6 (PP6) and the Casein Kinase 1 alpha 1 were identified to be 
involved in the modification of Ago2 824:34 cluster164. The relevance of PP6 in this process 
could also be verified in this work, especially its subunit ANKRD52. This phosphatase is a 
heterotrimeric complex consisting of a catalytic subunit PPP6C, a SAPS domain-containing 
subunit (PP6R1-3) and an ankyrin repeat-domain containing regulatory subunit (ANKRD28, 
44, 52)162,163. In the model of Golden et al.164, the PPP6C-ANKRD52 complex is necessary to 
dephosphorylate Ago to enable the association with new targets. Of note, PP6R1-3 were not 
found to be involved in this process although a CRISPR based genome-wide functional screen 
was performed. However, it is the current view that SAPS proteins serve as scaffolds for 
PPP6C and ANKRD proteins and are thus required for their function162,163. It remains still 
unknown, how PPP6C can assemble with ANKRD52 without SAPS proteins194. In the mass 
spectrometry analysis of Dr. Anne Frohn, SAPS3 or PP6R3, ANKRD28 and PPP6C could be 
detected as interacting partners of Ago2161. PP6 is ubiquitously expressed in mammalian 
tissues195. Depletion of PPP6C in mouse discovered its essential role in early 
embryogenesis196,197. An upregulated expression of PP6 could be detected in adipose tissues 
from insulin-resistant mouse models198, inflammatory bowel disease199 and various types of 
cancer200–202. In contrast, a downregulated expression of PP6 was observed in other types of 
cancer203,204. It is reported, that levels of PP6 can be controlled by miR-31 and miR-373 and 
this was linked to some types of cancer201,204,205. In human breast cancer, a decreased protein 
level of PP6, PP6R2 and PP6R3 could be detected. In addition, miR-373 was reported to act 
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as tumor-promoting miRNA in testicular germ cell tumors206, esophageal squamous cell 
carcinoma207, and hepatocellular carcinoma204. PP6 mRNA is a known target of miR-373, thus 
linking PP6 and hepatocellular carcinoma204. It would be very interesting, to measure 
phosphorylation of Ago in tumors and cancer models containing different levels of these 
factors. Additionally, the phosphorylation pattern of Ago should be detected after inhibition 
of miR-373, to see if there is a negative feedback loop between this special miRNA and Ago 
phosphorylation. Notably, an upregulation of AKNRD52 expression was found in lymphoid 
neoplasm diffuse large B-cell lymphoma, esophageal carcinoma, cholangio carcinoma, 
stomach adenocarcinoma and thymoma. A massive decrease in ANKRD52 expression was 
detected in uterine carcinosarcoma, uterine corpus endometrial carcinoma, thyroid 
carcinoma, ovarian serous cystadenocarcinoma, cervical squamous cell carcinoma and 
adrenocortical carcinoma, according to GEPIA database (www.gepia.cancer-pku.cn). In the 
Human Protein Atlas (www.proteinatlas.org), ANKRD52 was listed to be highly expressed in 
testis cancer, lung cancer and colorectal cancer. Dr. Hung Ho Xuan (postdoc in the department 
Biochemistry I, University of Regensburg) generated a mouse model for colorectal cancer in 
collaboration with Prof. Dr. Christina Hackl (University Hospital Regensburg)208. Here, the 
human colon cancer cell line HT29 was intrasplenically injected into female CB17 mice with 
an age of 6 weeks208. In future experiments, primary tumors and liver metastases will be used 
for characterization of the link between cancer, ANKRD52 upregulated expression and Ago 
phosphorylation at Ago2 824:34 cluster.  
The kinase CSNK1A1 identified in Golden et al.164 prefers previously phosphorylated 
substrates and recognizes the consensus sequence (pS/pT/E/D)-X1-2-S/T, which is already 
mono-phosphorylated209,210. Multiple phosphorylations often need a first kinase to set the 
priming phosphorylation and secondary kinases, which recognize the priming 
phosphorylation and facilitate subsequent hyper-phosphorylation211. Therefore, the 
question, of the identity of the priming kinase remains unanswered. Our mass spectrometry 
data suggests that S828 is the most likely priming site. Mutating this site into A, only 
phosphorylated S824 was found. This indicates that CSNK1A1 most likely only modifies S831 
and S834. So, three of five residues are probably phosphorylated by different kinases. Does 
the S824 also need an initial phosphorylated S828 or is this site phosphorylated separately? 
This question could be answered in future experiments, with the transfection of Ago2 S828A 
mutant in a CSNK1A1-deficient background, followed by detection of phosphorylation events. 
The site T830 is probably not phosphorylated by CSNK1A1, because Golden et al.164 detected 
no phosphorylation in an in vitro kinase assay when mutating all other residues into A. Again, 
the question rises, which kinase is responsible for phosphorylation at T830? 
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Figure 19 Peptide sequence of 824:34 cluster and summary of kinases. CSNK1A1 recognize previously 
phosphorylated S828 and phosphorylates S831 and subsequently S834. It is still unclear, which kinase is 
responsible for the phosphorylation of S824, S828 (priming site) and T830.  
 
Taken together, Ago2 contains a highly flexible loop on the surface of the PIWI domain, which 
has the potential to reach the target RNA. This exposed loop is easily accessible for kinases 
and phosphatases and it was indeed found to be hyper-phosphorylated. The loop containing 
the 824:34 cluster of Ago probably becomes hyper-phosphorylated by CSNK1A1 after 
repression (Figure 20) but it is also likely that other so far unknown kinases are involved. 
Negative charges of the phosphates repel the negative charged sugar-phosphate backbone of 
the mRNA leading to dissociation from the mRNA target. After target release, Ago might be 
dephosphorylated by the PP6 complex (Figure 20). These findings open many exciting 
questions: For example, is hyper-phosphorylation of Ago proteins a general mechanism for 
target release and subsequent target degradation? Do certain RNA binding proteins recruit 
target-specific kinases or phosphatases upon specific stimuli? Is the Ago2-phosphorylation 
state of the 824:34 cluster a mechanism to regulate distinct targets that need to be essentially 
expressed at specific timepoints in development? Will Ago be recycled once it is 
dephosphorylated and enter another repression round or will it be degraded? Answering 
these questions will be exciting future research directions in developmental, physiological 
and pathophysiological contexts.  
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Figure 20 Mechanistic model how Ago phosphorylation might be involved in miRNA-guided gene silencing. 
Ago is guided by miRNA to target RNA, GW182 proteins are recruited and translational repression and mRNA 
decay are initiated. After repression, Ago gets hyper-phosphorylated by CSNK1A1 and probably other kinases. 
Negative charges of the phosphates repel the mRNA and the target is released. After dephosphorylation by PP6, 
Ago might be recycled and guided to a new mRNA. The other possibility is that Ago is degraded and that 
phosphorylation functions as a decay signal. 
 
3.1.5 Phosphorylation of Ago proteins – outlook 
 
In this work, several phosphorylation sites on Ago proteins were identified by mass 
spectrometry. Besides the Ago cluster phosphorylations, it would be very interesting to 
characterize the remaining phosphorylation sites. This would provide new information about 
association with binding partners, like Dicer or TNRC6 proteins, cellular localization, binding 
of RNAs and general stepwise regulation.  
To better understand the relevance of Ago-mediated gene silencing, it is necessary to analyze 
its interaction network. Identifying kinases and phosphatases, which are involved in the de-
/phosphorylation events on Ago proteins is challenging, since e.g. kinase motif predictions 
are often ambiguous. Future approaches for the identification of kinases and phosphatases, 
which are involved in miRNA-guided gene silencing, could be for example microscope-based 
screenings. Here, a stable cell line expressing TNRC6A fused to GFP could be used in 
combination with red-labeled DNA oligonucleotides, which are perfect complementary to 
abundant mRNAs in the cells. When complexes composed of Ago, miRNA, mRNA and TNRC6 
form, combined colors will result in yellow spots. The idea is to use a siRNA library against 
kinases and phosphatases to knock down specific enzymes and to investigate, if the yellow 
spots disappear and red and green individual spots are detectable. This hints towards kinases 
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or phosphatases that are involved in the assembly or dissociation of miRNA-guided gene 
silencing complexes. These assays are currently established in the lab but are beyond the 
scope of this PhD thesis. 
For the identified phosphorylation sites, not only kinases and phosphatases are mainly 
unknown but also their impact on cellular signaling pathways remain elusive. It is published 
that phosphorylation of Ago2 at S387 is induced by cellular stress acting through the p38 
MAPK pathway135. CSNK1A1 participates in Wnt signaling and functions in a complex with 
Glycogen synthase kinase-3 (GSK3)212,213. The known phosphatase of Ago2 cluster PP6 is also 
a component of a signaling pathway regulating cell cycle progression in response to IL2 
receptor stimulation214. Additionally, PP6 downregulates Mitogen-activated protein kinase 
kinase kinase 7 (MAP3K7/TAK1) activation of the IL1 signaling pathway by de-
phosphorylation of TAK1215. Identifying and validating one or even more signaling pathways, 
Ago phosphorylation plays a role in, might be challenging but opens interesting future 
research directions. Furthermore, disease and cancer relation to Ago phosphorylations will 
be exciting research topics. For example, Shankar et al. published a connection between Ago2 
Y393 phosphorylation and EGFR-KRAS signaling in pancreatic cancer development216.  
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3.2 Ago2 mutations and the relation to neurodevelopmental disease 
 
Ago proteins are very important actors in the miRNA-guided gene silencing pathway. In 
difference to other proteins of the AGO family, Ago2 is essential for murine embryonic 
development. Knocking out Ago2 was lethal in every case217,218. Homozygous Ago2 catalytical 
mutant mice died directly after birth219. It is published that mis-regulated Ago expression 
levels can cause various diseases, like Huntington’s disease152 or cancer143,144,146,148,149. These 
findings emphasize the importance of intact Ago2, especially in embryonic development.  
In collaboration with Prof. Dr. Kreienkamp and Dr. Lessel (University Medical Center 
Hamburg-Eppendorf, Hamburg), genome sequencing of various children was performed. 
These children suffer from the same neurodevelopmental disorders: they show mental 
retardation and learn to talk and walk in a late stage. The sequencing resulted in the finding 
that only unexpected point mutations or deletion at different residues of only Ago2 are 
present in these children. Even more astonishing, these point mutations/deletion are 
heterozygous, i.e. an intact WT allele is still present in the genome. 
 
3.2.1 Functional analysis of Ago2 mutants 
 
Interestingly, all individual point/deletion mutants resulted in the same phenotype. 
Therefore, we asked the question what the mutations have in common to generate the same 
phenotype. 
In vitro analysis revealed that almost all mutants showed WT behavior in protein-protein 
interactions with Dicer and TNRC6 (Figure 15 B, C). Additionally, miRNA binding (Figure 15 
C), repression of a reporter mRNA (Figure 15 E), cleavage activity (Figure 15 D) and cellular 
localization was indistinguishable from WT Ago2 (Figure 16). However, one mutant, the 
G733R, failed in every assay and seemed to be catalytically dead. The arginine, which replaced 
the small glycine, probably disrupts the structure in a way that the protein loses its activity.  
Since we found that 824:34 cluster phosphorylation is important for the regulation of target 
mRNA binding, the phosphorylation of the 824:34 cluster was measured, relatively quantified 
and compared to WT Ago2 (Figure 17 A). All mutants showed reduced quadruple 
phosphorylated peptides of the 824:34 cluster. In contrast, the phosphorylation of S387 was 
at similar levels to WT. This excludes the possibility of poor-quality mass spectrometric 
measurements and serves as internal standard. According to the hypothesis in chapter 3.1.4, 
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hyper-phosphorylation of the 824:34 cluster leads to target release because of the repulsion 
of negative charges. Thus, all mutants might be impaired in dissociation from their mRNA 
target (Figure 17 A). Only the mutant H203Q gave a higher ratio of quadruple phosphorylated 
to non-phosphorylated peptide but with a large error bar. This indicates that the 
measurements differ a lot and the mass spectrometry analysis should be repeated with this 
mutant to get a reliable result. 
For validation of the mRNA binding model, RIP experiments were performed and analyzed 
via qRT-PCR (Figure 17 B). All mutants showed higher target enrichment in comparison to 
WT Ago2, except for the G733R mutant, which is the most likely structurally affected as 
discussed above. For control, the Ago2 mutant E186K was used. This mutation was found in 
people with no obvious abnormal phenotype. In qRT-PCR experiments, this mutant showed 
mRNA binding like WT as expected. The higher target RNA enrichment of the other mutants 
corresponds to the hypo-phosphorylation state of the mutants. Because, if they are not hyper-
phosphorylated, the mRNA is bound longer or tighter to the Ago protein. The mRNA release 
is probably hindered, which would result in a lower off rate or a higher affinity to mRNAs. 
This “slowdown of the system” may result in impaired development and the observed 
neurodevelopmental disorders. 
 
3.2.2 Structural localization of phenotypic Ago2 mutations 
 
The first cluster of mutations (F182del, L192P, G201C/V, H203Q) is placed in the linker 1, the 
next set (M364T, A367P) in linker 2 region and the last set of mutations (G733R, C751Y, 
S760R) in the PIWI domain (Figure 15 A). Looking into the human Ago2 crystal structure 
revealed that all mutations cluster around the α-helix-7. Two of the mutated amino acids, the 
M364 and A367, are directly located on that helix. Additionally, all mutations are close to the 
bound miRNA:mRNA hybrid (Figure 21).  
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Figure 21 Positioning of patient mutations in the crystal structure of human Ago2 with miRNA/mRNA.  
Mutations found in patients are shown in red. Parts of Ago2 are indicated in grey and the helix-7 is shown in yellow, 
based on the model 4W5O71. The miRNA is shown in orange, parts of the mRNA are indicated in green.  
 
Klum et al. identified Ago2 α-helix-7 as a structural element that is required for speed and 
fidelity in binding target RNAs220. They used biochemical, structural and single-molecule data 
to show that helix-7 acts as a molecular quality manager or catalyst for seed pairing of 
miRNA:mRNA. They hypothesize that helix-7 enables target pairing with the positions g6 and 
g7, which are base numbers of the guide RNA220. It is also suggested that the 5’ domain (g2-5) 
of the seed is held by Ago2 in an A-form like conformation73. The 3’ end of the seed (g6-8) is 
able to move between different conformations. This movement is controlled by helix-7, which 
raises the rates of mRNA pairing and un-pairing220. Helix-7 stably docks into the minor groove 
of the miRNA:mRNA duplex and is therefore able to break target binding220. When mutating 
the residues M364 and I365 to A, which are located on helix-7, the affinity of Ago2 to miRNAs 
was not affected220. In contrast, they observed a higher dwell time on off-targets with the 
mutated helix-7. They conclude that helix-7 also allows Ago2 to efficiently distinguish 
between targets and off-targets220. Interestingly, in this publication, M364 was mutated into 
A and showed a strong effect in mRNA binding. They also modeled the mutated helix-7 and it 
shifts backwards, away from the guide RNA220. Off-targets and on-targets have a slower off 
rate and probably block Ago2 for the next round of silencing.  
In one patient, a mutation of the same amino acid, M364 to T, was identified and is responsible 
for the phenotype since helix-7 is not able to function properly. Additionally, the position 
A367 was mutated into P in another patient. This residue is also located directly on the helix-
7. Proline is known to be a helix breaker, which may by the reason why helix-7 cannot be as 
functional as in a WT Ago2 protein. The mutations F182del, L192P, G201C/V and H203Q are 
located around helix-7 and close to the miRNA:mRNA duplex. In addition, these mutations 
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might influence target binding and therefore might be the reason for a changed binding 
pattern, which may result in a neurodevelopmental disease. Park et al. hypothesized that the 
N-terminal domain is involved in unwinding of the miRNA duplex221. When mutating F181 
into A, the pre-RISC could be formed successfully but its unwinding activity was much slower 
than WT Ago2221. The deletion of the neighboring phenylalanine F182 in patients might have 
the same effect. If the unwinding of the miRNA duplex were slower, this mutant would also 
not be accessible for mRNA at the time of bound miRNA duplex. It also would not be able to 
form a repressive complex in the period in which unwinding is not completed. The human 
Ago2 crystal structure displayed that aliphatic segments of the residues R795, I756 and Q757, 
which are located in the PIWI domain, and the residues I365 and T361 on helix-7 line the 
minor groove of the guide:target duplex73. These sites are making large hydrophobic and van 
der Waals interactions with the positions 2 to 7 of the miRNA:mRNA duplex73 (Figure 22). In 
patients, mutations of the residues G733, C751 and S760 were observed. Replacing these 
small residues into large amino acids like R or Y might lead to an internal shift of the protein, 
which might affect the interaction between the residues R795, I756 and Q757 with the minor 
groove of the RNA duplex and thus the correct target RNA binding.  
 
 
Figure 22 Positioning of patient mutations in relation residues interacting with the minor groove of 
guide:target duplex.  Parts of the crystal structure of Ago2 are shown in grey, based on the model 4W5O71. Patient 
mutations are indicated in red, miRNA in orange and parts of the mRNA in green. The blue dotted residues I756, 
Q757 and R795 interact with the minor groove of the guide:target duplex. Yellow marks helix-7 and the yellow 
dotted residues also line the minor groove.  
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3.2.3 Summary and outlook 
 
In summary, the commonality of all mutations, which were found in patients with the same 
phenotype, is their localization around the guide:target duplex. These mutants affect the 
target binding in a way that either off- and on-targets are bound stronger/longer to the 
miRNA-Ago2 protein complex or the miRNA duplex unwinding is slower during loading of 
miRNAs into Ago2. Another reason might be that the helix-7 cannot function as a quality 
manager with the mutations, uncovering off-target mRNAs. In conclusion, all mutants are 
unable to bind or release the targets or off-targets in a correct way. This would indicate that 
a part of the real miRNA targets could only be repressed in a reduced fashion, because the 
defect Ago2 is blocked by off-targets or the prolonged repression of on-targets gives the 
phenotype. Of note, the Ago2 G733R mutant seems to be catalytically dead but results in the 
same neurodevelopmental phenotype, whereas all other mutants showed WT behavior in 
most of the functional analyses. This does not fit completely in the model and the link to the 
other mutations remains still not fully clear. It should also be checked again, if G733R is the 
only mutation in this patient. 
Of note, two mutations, G201V and C751Y, were identified at a later stage and could not be 
included in this work. These mutations should be characterized in functional assays, 
especially on phosphorylation of the 824:34 cluster and mRNA binding. In addition, the F182 
deletion mutant should be analyzed upon its ability to unwind the miRNA duplex.  
Another important point is the heterozygous occurrence of the mutations. This means that an 
intact Ago2 is present besides the mutated version. In consequence, two fully functional Ago2 
alleles are necessary for a correct neurological development in humans. It would be very 
interesting to generate mutant mice and look for similar phenotypes. The mouse models 
might reveal new insights in neurological developmental delay and its relation to Ago2 
mutations.  
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4 Material and Methods 
4.1 Consumables and chemicals 
 
All used chemicals were obtained from Sigma-Aldrich (St. Louis, USA), Merck (Whitehouse 
Station, USA), Roth (Karlsruhe, Germany), AppliChem GmbH (Darmstadt, Germany) and 
Thermo Fisher Scientific (Waltham, USA). They were ordered at the highest degree of purity. 
Radiochemicals were purchased from Hartmann Analytic GmbH (Braunschweig, Germany). 
Oligonucleotides were synthesized by Metabion GmbH (Planegg, Germany) and cell culture 
reagents were obtained from Sigma-Aldrich (St. Louis, USA). Frequently used enzymes, 
nucleotides, and molecular weight markers were purchased from Thermo Fisher Scientific 
(Waltham, USA). 
 
4.2 Buffers and solutions 
 
name contents 
2 ×HEPES-buffered saline  274 mM NaCl, 1.5 mM Na2HPO4, 54.6 mM HEPES (pH 7.1) 
NET buffer  50 mM Tris/HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.5 % 
NP-40,  
10 % Glycerol, 1 mM NaF, 0.5 mM DTT, 1 mM AEBSF 
NET washing buffer NET buffer with 300 mM NaCl  
RIPA buffer  50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 0.1 % SDS, 1 % 
sodium deoxycholate,1 % NP-40, 1 mM NaF, 0.5 mM DTT, 1 
mM AEBSF 
5 × SDS sample buffer 
(Lämmli) 
 
300 mMTris/HCl pH 6.8, 10 % SDS, 62.5 % glycerol, 0.05 % 
bromophenol blue, 
10 % β-mercaptoethanol 
SDS-Running buffer  25 mM Tris, 192 mM glycine, 1 % SDS 
Towbin Blotting Buffer 25 mM Tris, 192 mM glycine, 20 % methanol (pH 8.6) 
TBS-T 10 mM Tris, 150 mM NaCl, 0.1 % Tween (pH 8) 
2 × RNA sample buffer bromophenol blue and xylene cyanol in formamide 
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10 × TBE  890 mM Tris, 890 mM boric acid, 20 mM EDTA 
20 × SSC  3 M NaCl, 0.3M trisodium citrate (pH 7) 
50 × Denhardt’s solution  1 % Bovine serum albumin fraction V, 1 % 
Polyvinylpyrrolidon K30, 1 % Ficoll 400 
Hybridization solution 1 × SSC, 20 mM Na2HPO4 pH 7.2, 7 % SDS, 1 × Denhardt’s 
solution 
Wash buffer I 5 × SSC, 1 % SDS 
Wash buffer II 1 × SSC, 1 % SDS 
10 × GT buffer  400 mM Tris pH 8, 60 mM MgCl2, 150 mM DTT, 20 mM 
spermidine 
carrier RNA solution  25 µM sodium citrate pH 5.0, 7.5 M urea, 1 mM EDTA, 0.1 
µg/µl yeast tRNA (Ambion), 0.05 % bromophenol blue, 0.05 
% xylene cyanol 
RNase T1 dilution 25 µM sodium citrate pH 5.0, 7.5 M urea, 1 mM EDTA, 5 U/µl 
RNase T1 (Fermentas),0.05 % bromophenol blue, 0.05 % 
xylene cyanol 
Renilla Luciferase buffer 
pH 5.0 
2.2 mM Na2EDTA, 0.22 M KxPO4 pH 5.1, 0.44 mg/ml BSA, 1.1 
M NaCl, 1.3 mM NaN3  
Firefly Luciferase buffer 470 µM D-luciferine, 530 µM ATP, 270 µM coenzyme A, 20 
mM tricine, 5.34 mM magnesium sulfate heptahydrate, 0.1 
mM EDTA 
3 × Translation Mix 200 mM KCl, 20 mM MgCl2, 25 mM DTT, 5 mM ATP, 1 mM 
GTP, 
0.5 U/µl RiboLock RNase Inhibitor 
Coomassie Staining  10 % acetic acid, 30 % ethanol, 0.25 % Coomassie R250 
Coomassie Destaining 10 % acetic acid, 20 % ethanol 
Table 1 Buffers and solutions 
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4.3 Bacterial strain and cell lines 
 
The bacterial strain XL1-blue was used in this work. (Genotype: F- recA1 enA1 gyrA96 thi-1 
hsdR17 supE44 relA1 lac F’[proAB lacIqZΔM15 Tn10 (TetR)]) 
The cell lines are listed in Table 2. 
cell line specification 
HEK 293T human embryonic kidney cells 
HeLa human cervical cancer cells 
H32 rat hypothalamic cells 
MEF Ago2-/- mouse embryonic fibroblast cells, Ago2 knock out (k.o.) 
Table 2 cell lines 
 
4.4 Vectors, constructs and oligonucleotides 
4.4.1 Vectors 
 
Used vectors are listed in Table 3. 
vector name resistance tag applications 
VP5 Amp N-terminal HA- and FLAG-tag eukaryotic expression vector 
pCIneo NHA Amp λ-phage N-peptide followed 
by HA-tag 
mammalian expression 
vector tethering assays 
pCIneo HA  HA-tag mammalian expression 
vector tethering assays 
Table 3 Vectors 
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4.4.2 Constructs 
 
FLAG/HA-tagged GFP and human Ago2 were described before77. Ago2 824:34A/E and 
555:61A/E mutants were generated by 3-way blunt end ligation (Dr. Judith Hauptmann, 
University of Regensburg)154. To obtain the Ago2 mutants, ‘Quik-Change’ PCR strategy (site-
directed mutagenesis) was used. For tethering assays, the constructs were cloned into the 
mammalian expression vector pCIneo via NotI/EcoRI.  
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4.4.3 Oligonucleotides 
 
All used oligonucleotides were diluted in water to a concentration of 10 µM (primers) or 20 
µM (probes) and stored at -20°C. The oligonucleotides used for cloning are listed inTable 4, 
others are listed in Table 5.  
 
construct name orientation primer sequence (5’→3’) 
Ago2 F182del_2 fwd GCCGCTCCTTCACCGCGTCCGAAGGCTGCTCTAA  
Ago2 F182del_2 rev TTAGAGCAGCCTTCGGACGCGGTGAAGGAGCGGC  
Ago2 E186K fwd CTTCACCGCGTCCAAAGGCTGCTCTAAC  
Ago2 E186K rev GTTAGAGCAGCCTTTGGACGCGGTGAAG  
Ago2 L192P  fwd GAAGGCTGCTCTAACCCTCCTGGCGGGGGCCGAGAAGTG 
Ago2 L192P  rev CACTTCTCGGCCCCCGCCAGGAGGGTTAGAGCAGCCTTC  
Ago2 G201C  fwd CGAGAAGTGTGGTTTTGCTTCCATCAGTCCG  
Ago2 G201C  rev CGGACTGATGGAAGCAAAACCACACTTCTCG  
Ago2 H203Q  fwd GGTTTGGCTTCCAGCAGTCCGTCCGGC  
Ago2 H203Q  rev GCCGGACGGACTGCTGGAAGCCAAACC  
Ago2 M364T  fwd CAGACCTCAACCACGATCAGAGCGACTG  
Ago2 M364T  rev CAGTCGCTCTGATCGTGGTTGAGGTCTG  
Ago2 A367P fwd CAACCATGATCAGACCGACTGCTAGGTCG 
Ago2 A367P rev CGACCTAGCAGTCGGTCTGATCATGGTTG  
Ago2 A620W  fwd GCAGCATGGACTGGCACCCCAATCGCTACT 
Ago2 A620W  rev AGTAGCGATTGGGGTGCCAGTCCATGCTGC  
Ago2 L694W  fwd GCCTGTATCAAGTGGGAAAAAGACTAC 
Ago2 L694W  rev GTAGTCTTTTTCCCACTTGATACAGGC 
Ago2 G733R  fwd GAAACATTCCAGCACGCACGACTGTGGAC  
Ago2 G733R  rev GTCCACAGTCGTGCGTGCTGGAATGTTTC  
Ago2 S760R  fwd CATCCAGGGGACACGCAGGCCTTCGC  
Ago2 S760R  rev GCGAAGGCCTGCGTGTCCCCTGGATG  
Table 4 Oligonucleotides for cloning 
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oligonucleotide orientation sequence (5’→3’) 
Probes for Northern 
Blotting 
  
miR-19b fwd TCAGTTTTGCATGGATTTGCACA 
miR-21 fwd TCAACATCAGTCTGATAAGCTA 
let-7a fwd AACTATACAACCTACTACCTCA 
Sequencing primers   
T7 fwd TAATACGACTCACTATAGGG 
M13 fwd TGTAAAACGACGGCCAGT 
M13 rev CAGGAAACAGCTATGACCATG 
pCIneo Seq rev TGCATTCTAGTTGTGGTTTG 
pCIneo fwd fwd GCGTTTCTGATAGGCACCTATTG 
Ago2 seq1 fwd GGCACAGCCAGTAATCGAGT 
Ago2 seq2 fwd CGGAAGTCCATCTGAAGTCCT 
Table 5 Oligonucleotides for Northern Blotting and sequencing 
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4.5 Antibodies 
 
antibody origin application dilution supplier 
antibodies against 
endogenous proteins 
    
α-Ago2, clone 11A9 rat WB, IP 1:5 Dr. E. Kremmer/Dr. 
Regina Feederle, 
Helmholtz Zentrum 
München 
α-TNRC6A-C, clone 7A9 rat WB, IP 1:5 
 
antibody against tags 
    
α-HA, clone 16B12 mouse WB 1:1000 Covance Research 
Products 
secondary antibody     
α rat IRDye® 800CW goat WB 1:10000 LI-COR Bioscience 
α mouse IRDye® 800CW goat WB 1:15000 LI-COR Bioscience 
Alexa Fluor 488 mouse IF 1:400 Thermo Fisher 
Scientific 
Alexa Fluor 555 chicken IF 1:400 Thermo Fisher 
Scientific 
Table 6 primary and secondary antibodies.  WB: Western Blot, IP: immunoprecipitation, IF: immunofluorescence 
 
4.6 Technical Equipment 
 
For imaging of Western Blots Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, 
USA) was used. The supplier of Personal Molecular ImagerTM (Phosphorimager) is Bio-Rad 
Laboratories (Hercules, USA).  
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4.7 Producing DNA constructs 
4.7.1 Polymerase chain reaction (PCR) 
 
All mutants in this thesis were generated by site-directed mutagenesis (‘Quik Change’). This 
PCR method uses mutagenic primers to change or delete single/several amino acids. After 
amplification, the template DNA was removed by DpnI digestion. The components and 
conditions of the PCR reaction are listed below.  
PCR Mix 50 µl  Cycling Conditions   
50 ng template DNA Initial denaturation 98°C 30 s 
1× HF buffer Denaturation 98°C 10 s 
0.2 mM dNTPs Annealing 55°C 30 s 
0.2 µM reverse primers Elongation 72°C 1 min/kb 
0.2 µM forward primers Terminal elongation 72°C 10 min 
1 U Phusion DNA Polymerase    
    18 cycles 
 
After the PCR reaction and DpnI digestion, the products were purified by NucleoSpin® Gel 
and PCR Clean-up kit (MACHEREY-NAGEL GmbH). For preparative digestion, FastDigest 
restriction enzymes (Thermo Fisher Scientific) were added to the whole PCR reaction and 
incubated at 37°C for 3-6 h. Afterwards, the DNA was separated on a 1 % agarose gel and 
purified by the kit named above.  
Ligation were performed with 50 ng of the cut vector and 4× molar excess of the restricted 
insert, 0.1 U/µl T4 Ligase (Thermo Fisher Scientific), appropriate buffers and PEG 4000. The 
reaction was incubated for 1 h at 23°C, followed by transformation. 
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4.7.2 Transformation of Escherichia coli (E. coli) with plasmids 
 
After defrosting chemically competent E. coli cells (XL1-Blue), approximately 0.5 µg plasmid 
DNA was added and were incubated for 20 min on ice. Afterwards, the cells were incubated 
at 42°C for 1 min, followed by a cooling step on ice. An additional incubation step in antibiotic-
free LB-medium at 37°C is not necessary, because Ampicillin, as a beta-lactam antibiotic, 
inhibits the cell-wall synthesis of bacteria. At the end, they were plated on LB-Amp plates and 
incubated over night at 37°C. For retransformations, 30 µl were plated containing LB medium 
and Ampicillin.  
 
4.7.3 Preparation of plasmid DNA from E. coli 
 
A 5 ml overnight culture was centrifuged at 15,000 g and the DNA was purified with the 
NucleoSpin® Plasmid Kit of MACHEREY-NAGEL GmbH according to the manufacturer’s 
protocol. Plasmid DNA was eluted with 50 µl dH2O. For fast DNA extraction, 2 ml of the 
overnight culture were pelleted and resuspended in 40 µl EasyPrep Buffer. The samples were 
incubated at 99°C for 1 min, followed by a 15 min centrifugation at 15,000 g. For restriction 
analysis, 5 µl of the supernatant were digested with 0.1 µl FastDigest enzyme(s) (Thermo 
Fisher Scientific) in a total volume of 10 µl.  
The plasmid DNA was sequenced by Macrogen (Amsterdam, The Netherlands) with the 
sequencing primers listed in Table 5. 
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4.8 Protein-based methods 
4.8.1 Cell culture 
 
Human cells (HEK 293T, HeLa) were cultivated under standard conditions (37°C, 5 % CO2) 
using Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich) including 10 % FBS 
(Sigma-Aldrich) and 1 % Penicillin/Streptomycin (Sigma-Aldrich).  
 
4.8.1.1 Transfection by calcium phosphate 
 
HEK 293T cells were transfected using calcium phosphate. 5-10 µg DNA and 123 µl 2 M CaCl2 
were filled up to 1 ml with water in one reaction tube. This mixture was added to a second 
tube containing 1 ml 2 × HEPES buffered saline while shaking. After 10 min incubation, the 
whole 2 ml solution was added to the cells with about 30 % confluency on a 15 cm plate. The 
cells were harvested after 48 h. 
 
4.8.1.2 Transfection by Lipofectamin 2000 
 
HeLa or MEF Ago2 -/- cells were transfected with Lipofectamin 2000 (Thermo Fisher 
Scientific) and Optimem according to the manufacturer’s protocol. Here, a reverse 
transfection was used. For tethering assay, 300 ng λ-NHA/HA-constructs, 120 ng Renilla-
5BoxB luciferase and 80 ng Firefly luciferase were filled up to 25 µl with Optimem per well of 
an 48 well-plate. In a second reaction, 1 µl Lipofectamin 2000 was mixed with 24 µl Optimem. 
After adding the DNA solution to the Lipofectamin 2000 solution, it was incubated for 10 min 
and applied to the medium. The cells were then split on the 48 well-plate onto medium 
supplemented with the Lipofectamin-DNA mix. For luciferase reporter assays, 400 ng of VP5-
Ago2 constructs and 125 ng of the plasmid encoding for Firefly luciferase mRNA under 
control of HMGA2 3’ UTR and the mRNA of a Renilla luciferase as transfection control were 
cotransfected. For Immunofluorescence (IF), cells were transfected with 300 ng VP5-Ago2 
constructs.  
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4.8.1.3 Transfection by Lipofectamin RNAiMAX 
 
For knockdown experiments with a subsequent mass spectrometry analysis, Lipofectamin 
RNAiMAX (Thermo Fisher Scientific) was mixed with 16 µl of 10 µM siPool (siTools, Munich) 
in Optimem, according to the manufacturer’s protocol. The mixture was supplemented to the 
cell culture media and HEK 293T cells were seeded on 10 cm plates to a confluency of about 
60-80 %. After 24 h, cells were transferred to 15 cm plates, followed by splitting on three 15 
cm plates 48 h after transfection. Finally, the cells were harvested 72 h after transfection.  
 
4.8.2 Lysate preparation from harvested cells 
 
For harvesting cells, the medium was completely removed and the cells were washed with 
cold PBS once. To scrape the cells off the plate, a rubber policeman was used and the cell 
suspension was transferred into a 1.5 ml reaction tube. After 10 min centrifugation at 200 g, 
the supernatant was removed and the cells were lysed in 1 ml NET lysis buffer, respectively. 
Generally, an incubation time of 20 min on ice and a centrifugation step for 20 min at 15,000 
g were applied.  
 
4.8.3 Immunoprecipitation (IP) 
 
For immunoprecipitation of endogenous proteins, monoclonal antibodies were coupled to 
Protein G Sepharose (GE Healthcare). Therefore, 30-100 µl beads were washed with cold PBS 
twice and incubated with 1-5 ml hybridoma supernatant overnight. The beads were washed 
with cold PBS twice to remove unbound antibody. Thereafter, the lysate was added to the 
beads and incubated for 2 h at 4°C. For an IP of TNRC6, an only 1.5 h rotation step is necessary. 
For immunoprecipitation of overexpressed FLAG/HA-tagged proteins, anti-FLAG M2 affinity 
agarose gel (Sigma-Aldrich) was used and washed twice with cold PBS before incubation with 
lysate. After incubation, the beads with bound proteins were centrifuged for 1 min at 1000 g 
and the supernatant was removed. The affinity matrix was washed with lysis buffer three 
times, followed by washing with PBS once. In the last washing step, a new reaction tube was 
used to minimize the contamination by protein bound to the reaction tube surface. Finally the 
beads were eluted by addition of an appropriated amount of 2.5 × Laemmli sample buffer. 
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4.8.4 SDS-PAGE, Western Blot and Coomassie staining 
 
After elution, half of the volume was loaded on 10 % SDS polyacrylamide gels. The gels were 
run at 180 V.  
Stacking gel 125 mM Tris/HCl pH 6.8, 0.1 % SDS, 0.15 % 
TEMED, 5 % Acrylamide/Bis solution 
(37.5:1), 0.05 % APS 
Resolving gel 380 mM Tris/HCl PH 8.8, 0.1 % SDS, 0.1 % 
TEMED, 6–10 % Acrylamide/Bis solution 
(37.5:1), 0.05 % APS 
 
For Western Blot analysis, a stack of three Whatman papers and a Hybond ECL membrane 
(GE Healthcare), matching the size of the gel, were soaked with 1 ×Towbin Blotting Buffer and 
placed on the positive electrode. The SDS gel was put above, followed by three soaked 
Whatman papers. The semi dry Western Blot was run at 10 V for 1.5 h. For bigger proteins, 
wet blot was used and run for 16 h at 30 V and 4°C. After blotting, the membrane was blocked 
in 5 % milk in 1x TBS-T for 1 h. The primary antibody was incubated also for at least 1 h at 
room temperature (RT), if possible overnight at 4°C in blocking solution. To remove unbound 
antibody, the membrane was washed with TBS-T three times. Thereafter, the secondary 
antibody was incubated for 1 h in blocking solution, the blot was washed three times and 
scanned with the Odyssey Infrared Imaging System (BioRad). 
For Coomassie staining, the SDS PAGE is incubated right after running in Coomassie solution 
for about 1 h. After staining, the gel gets destained in destaining solution and changed several 
times until the protein bands can be distinguished from the rest of the gel.  
 
4.8.5 Mass Spectrometry 
 
Phosphorylation site identification 
Distinct bands of an SDS-gel after affinity-purification were excised and washed with 50 mM 
NH4HCO3, 50 mM NH4HCO3/acetonitrile (3:1), 50 mM NH4HCO3/acetonitrile (1:1) and 
acetonitrile. After washing, the samples were lyophilized for 1 h. For reduction and alkylation 
of cysteines, the gel pieces were incubated with DTT and Iodoacetamide, followed by the 
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washing steps and the lyophilization mentioned above. After in gel tryptic digest overnight at 
37 °C with approximately 2 µg trypsin per 100 µl gel volume (Trypsin Gold, mass 
spectrometry grade, Promega), Peptides were first extracted with 100 mM NH4HCO3, 
followed by 50 mM NH4HCO3 in 50 % acetonitrile. The eluates were combined, lyophilized 
and reconstituted in 20 µl 1 % TFA prior LC-MS/MS. The peptides were separated by 
reversed-phase chromatography on an UltiMate 3000 RSLCnano System (Thermo Fisher 
Scientific, Dreieich) which was equipped with C18 Acclaim Pepmap100 preconcentration 
column (100 µm i.D.x20 mm, Thermo Fisher Scientific). For the separation of the peptides, a 
linear gradient of 4 % to 40 % acetonitrile in 0.1 % formic acid over 90 min at a flow rate of 
300 nl/min. Via a CaptiveSpray nanoflow electrospray source, the LC was coupled to a maXis 
plus UHR-QTOF System (Bruker Daltonics, Bremen). Data-dependent acquisition of MS/MS 
spectra by CID fragmentation was done at a resolution of minimum 60000 for MS and MS/MS 
scans. The MS spectra rate of the precursor scan was 2 Hz processing a mass range between 
m/z 175 and m/z 2000. Via the Compass 1.7 acquisition and processing software (Bruker 
Daltonics) a dynamic method with a fixed cycle time of 3 s and an m/z dependent collision 
energy adjustment between 34 and 55 eV was used. Via Data Analysis 4.2 (Bruker Daltonics), 
raw data were processed. For database search, Protein Scape 3.1.3 (Burker Daltonics) in 
connection with Mascot 2.5.1 (Matrix Science) was applied. The following search parameters 
were used: enzyme specificity trypsin with two missed cleavages allowed, precursor 
tolerance 10 ppm, MS/MS tolerance 0.04 Da, variable modifications: propionamide 
modification and carbamidomethylation of cysteine, oxidation of methionine, deamidation of 
asparagine and glutamine, phosphorylation of serine, threonine and tyrosine. With a Mascot 
peptide ion-score cut-off of 15, phosphopeptide fragment sprectra were evaluated using 
Biotools 3.2 (Bruker Daltonics)160. 
 
SRM-quantification of phosphopeptides 
For phosphorylation stoichiometry determination of selected phosphopeptides, stable 
isotope-labeled peptides in phosphorylated and unphosphorylated state were used as 
internal standards. Heavy labeled peptides were synthesized as quantified SpikeTides-TQL 
(JPT Innovative Peptide solutions) with a 13C15N-labeled C-terminal lysine or arginine:  
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SASFNTDPYVR SApSFNTDPYVR 
YHLVDKEHDSAEGSHTSGQSNGR YHLVDKEHDpSAEGSHTSGQSNGR, 
YHLVDKEHDpSAEGpSHTpSGQpSNGR 
 
100 fmol of each labeled peptide were spiked into the samples before the overnight in-gel 
tryptic digests. The samples were then processed as described above. To generate a SRM 
(Selected Reaction Monitoring) method, the software Skyline (MacCoss Lab Software, Seattle, 
USA) was used. The first step is to build a spectral library from several LC-MS/MS discovery 
runs (DDA, data dependent analysis) on the hybrid triple quadrupole/linear ion trap 
instrument QTRAP4500 (SCIEX). According to their occurrence in the DDA runs, precursor 
charge states +2, +3, +4 with either 3 or 4 transitions were included in the targeted method 
and the resulting transition list was imported into the instrument software (Analyst 1.6.1). 
Additionally, the parameters were set for the SRM method: Q1 and Q3 set to unit resolution 
(0.7 m/z half-maximum peak width), dwell time 20 ms, cycle time < 3 s. Next, a scheduled 
SRM method was generated in Skyline by annotating peptide retention times from the initial 
SRM run and setting the parameters with a cycle time of 2 s and a retention time window of 
5 min. The LC-MS/MS system consisted of an UltiMate 3000 RSLCnano System (Thermo 
Fisher Scientific, Dreieich) coupled via NanoSprayII source (SCIEX) to a QTRAP4500. Peptide 
separation was conducted on an Acclaim Pepmap100 C18 preconcentration column (100 µm 
i.D.x20 mm, Thermo Fisher) in front. The run was performed at a flow rate of 300 nl/min on 
a 60 min linear gradient of 4 % to 40 % acetonitrile in 0.1 % formic acid. After importing the 
.wiff files of the SRM measurements into Skyline, the quantification of phosphorylated or non-
phosphorylated peptides was conducted by calculating the heavy-to-light ratios of the peak 
areas of the respective transitions. With the whole amount of detected peptides were set to 
100 %, the phosphorylated peptides could be relatively quantified160.  
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4.9 RNA-based methods 
4.9.1 RNA isolation 
 
For cleavage assays and Northern Blotting, RNA was isolated with 1 ml TRIzol (Thermo Fisher 
Scientific) and 200 µl cloroform. The samples were shaken vigorously for 15 sec and 
centrifuged at 15,000 g for 10 min. For RNA precipitation, the aqueous phase were 
transferred into 2.5 volumes of ethanol and 1 µl Glycogen RNA grade (Thermo Fisher 
Scientific) and incubated overnight at -20°C. Subsequently, RNA was pelleted by 
centrifugation at 15,000 g for 30 min. After a washing step with 70 % ethanol, the RNA pellet 
was resuspended in water or 2 × RNA sample buffer.  
 
4.9.2 RNA separation by Urea polyacrylamide gels and Northern Blotting 
 
For RNA separation, 8–12 % Urea polyacrylamide gels (Rotiphorese, Roth) were used. After 
a pre-run at 400 V in 1x TBE, the wells were washed and the RNA samples were loaded to the 
bottom of each well. 8 % urea gels were run at 400 V for 1 h, 12 % gels run 1.5 h.  
The Northern Blot was performed with three Whatman papers soaked with bidest. water and 
an Amersham Hybond-N membrane (GE Healthcare), which were placed on the positive 
electrode. The gel was washed with water, and put on the stack, followed by three bidest. 
water soaked Whatman papers. Northern Blotting was performed at 20V for 30 min. 
Thereafter, the RNA 5’ ends were crosslinked to the membrane via EDC crosslinking solution. 
EDC supports the phosphoramidate bond between 5’-phosphate of RNA and amine of the 
membrane. A Whatman paper was soaked with this solution, the membrane was placed on 
this paper with the RNA side facing up, wrapped in cling film and incubated at 50°C for 1 h. 
Probes, listed in Table 5, were labeled with 32P-γ-ATP on the 5’ end by T4 Polynucleotide 
Kinase (Thermo Fisher Scientific) at 37°C for 30 min. The reaction was stopped by adding 30 
µl 30 mM EDTA and purified by Sephadex G25 columns (GE Healthcare) to purify labeled 
probes from free 32P-γ-ATP. 
After crosslinking, the membrane was washed with water and dried. The radioactively 
labeled probe was incubated with the membrane in hybridization solution at 50°C overnight. 
After washing steps with wash-buffer I twice and with wash-buffer II once ten minutes each, 
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the blot was wrapped in cling film, exposed to a screen and scanned with phospho-imaging 
system (BioRad). 
 
4.9.2.1 Quantitative real-time PCR (qRT-PCR) 
 
The RNA of Input and IP samples were isolated using TRIzol (Thermo Fisher Scientific) and a 
second step with chloroform. For cDNA synthesis, 1 µg of the Input and complete RNA yield 
of the IP samples were first digested with DNaseI (Thermo Fisher Scientific). After the digest, 
cDNA was synthesized using First Strand cDNA synthesis kit (Thermo Fisher Scientific) with 
random hexamers, following the manufacturer’s protocol. qRT-PCR was performed with Sso 
Fast Eva Green Mix (Bio-Rad). The primer which were used in this thesis are: ST6GALNAC6, 
fwd 5’-CATTCGTGGTTGAGCACAGG, rev 5’-CCGCTGGCTGCAGTAGTT; NFIC, fwd 5’-
GACCTGTACCTGGCCTACTTTG, rev 5’-CACACCTGACGTGACAAAGCTC; SERBP1, fwd 5’-
ACATCCATAATCAGCCACCA, rev 5’-AAGCTGTCTGCTGCCCAAAT222; HMGA2, fwd 5’-
CTGCTATACACAAGCAATGCAAG, rev 5’-GTAAGGAGATTGCTTCTTTAACTG222, F8A1, fwd 5’-
GTTTGCGTCTGGGGAGGAAT, rev 5’-TGGTAACGTTCAGCCAACGA; HAND1, fwd 5’-
GGAGTCCGCAGAAGGGTTAAA, rev 5’-CGGGCAAGGCTGAAAATGAG; HOXC8, fwd 5’-
CGGAGACGCCTCCAAATTCT, rev 5’-GCCTTGTCCTTCGCTACTGT. qRT-PCRs were run on a 
CFX96 cycler (Bio-Rad) and data was analyzed using ΔΔCt method.160 
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4.9.3 RISC cleavage assay 
4.9.3.1 In vitro transcription  
 
The composition of an in vitro transcription reaction is listed below. 
 
In vitro transcription, 200 µl 
NTPs 20 mM 
DTT 10 mM 
Triton X-100 1 % 
Spermidin 2 mM 
MgCl2 25 mM 
Tris/HCl pH 8 30 mM 
template (here 86.1) 10 µg 
pyrophosphatase 0.2 µl 
T7 RNA polymerase 20 µg 
Table 7 Components of in vitro transcription reaction 
 
A T7 RNA Polymerase (purified by Dres. Nora Treiber and Thomas Treiber, Biochemistry I, 
University of Regensburg) was used for in vitro transcriptions. The reaction was incubated at 
37°C for 3-4 h. After incubation, 40 U DNase I (Thermo Fisher Scientific) were added and 
incubated for 15 min at 37°C to remove template DNA.  
For in vitro transcription, 400 ng of the DNA template were used. The in vitro transcribed RNA 
was separated on an 8 % urea gel. The transcription product was visualized by UV shadowing 
and excised. After elution from gel by RNA Elution Buffer at 65°C for 1 h while shaking, the 
liquid was transferred in a new reaction tube. The RNA was precipitated with 2.5 volumes of 
ethanol and resuspended in bidest. water. 
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4.9.3.2 Cap-labeling of the target RNA 
 
For cap-labeling, the in vitro transcribed RNA was incubated in a cap labelling reaction for 4 
h at 37°C. The cap-labeled RNA was separated on an 8 % urea polyacrylamide gel, visualised 
by UV shadowing, excised, and eluted from gel incubating in RNA Elution Buffer at 10°C over 
night while shaking. Thereafter, the RNA was precipitated in 2.5 volumes ethanol and pelleted 
by centrifugation for 30 min at 15,000 g. The supernatant was removed and the RNA pellet 
was resuspended in 15 µl bidest. water. 
 
cap labeling reaction, 20 µl 
GT buffer 1 × 
S-Adenosyl methionine 25 µM 
RiboLock RNase Inhibitor 0.5 U/µl 
Guanylyltransferase 10 % 
32P-α-GTP 1 µCi/µl 
Table 8 Composition of a cap-labeling reaction 
 
4.9.3.3 RISC cleavage assay 
 
The cleavage reaction was performed directly after anti-FLAG immunoprecipitation. The 
beads were washed as described before. 25 % of the total immunoprecipitate was separated 
for subsequent analysis by Western Blotting. Thereafter, translation mix was added to a final 
concentration of 1 × translation mix and the reaction was started by addition of 1-2 Bq/cm2 
cap-labeled target RNA per sample. The reaction was incubated for 0-1.5 h at 37°C and 
stopped by addition of TRizol (Thermo Fisher Scientific) and Cloroform, shaking and 
centrifuging, followed by precipitation overnight at -20°C in ethanol with 20 µg glycogen RNA 
grade (Thermo Fisher Scientific). After pelleting, the RNA was resuspended in 10 µl RNA 
sample buffer.  
The radiolabeled target RNA was also partially digested by RNase T1 and was used as ladder 
in for cleavage assays. For this reaction, 83.6 µl of carrier RNA solution and 4 µl of RNase T1 
were mixed and added to 1-2 Bq/cm2 radiolabeled target RNA. The mixture was incubated at 
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50°C for 10 min. Thereafter, the reaction was immediately transferred to -20°C. 2 µl of this 
ladder were loaded on the sequencing gel77,154,223. 
 
4.9.4 Autoradiographic sequencing gels 
 
Samples of RISC cleavage assays were loaded onto 8 % urea sequencing gels (Rotiphorese, 
Roth). The sequencing gel was poured and run in a SequiGen Sequencing Cell (21x40 cm, 0.4 
mm spacers, 16-well plastic comb, supplied by BioRad-Laboratories). The glass plate 
connected to the buffer tank was treated with Sigmacote® (Sigma-Aldrich) to facilitate gel 
pouring and disassembly, the other one was treated with 1 M NaOH, to increase roughness. 
Each well was washed before loading the samples. For loading MiniFlex Flat tips (Sorenson 
BioScience) were used. The gel was run at 50 W for about 1.5 h. After running, the gel was 
transferred onto Whatman paper, wrapped with cling film and vacuum-dried at 80°C for 1 h. 
Then, the gel was exposed to a screen and scanned at a phospho-imaging system (BioRad). 
 
4.10 Tethering Assays 
 
HeLa cells were transfected in triplicates as described above (4.8.1.2). After 48 h, the medium 
was completely removed and the cells were lysed by addition of 100 µl 1x Passive Lysis buffer 
(Promega, Madison, USA). The cells were shaken at 600 rpm for 15 min at RT. Thereafter, 20 
µl of each sample were transferred into 96-wells and used for measurements. For 
measurements, the Luciferase-Reader (Berthold) was used in combination with Renilla- and 
Firefly-buffers. Shortly before use, 10 µl of the Renilla substrate coelenterazine (1.43 mM) 
were added to 10 ml Renilla buffer, and 333 µl DTT (1 M) were added to 10 ml Firefly buffer. 
For control, blanks and cells transfected with empty vectors (pCI neo) were measured. The 
ratio of Firefly:Renilla-reads was used for evaluation and the reads of the NHA-tagged plasmid 
samples were normalized with the appropriate HA samples. 
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4.11 Dual Luciferase Assay 
 
For the dual luciferase assay, HeLa cells were cotransfected with 125 ng pMIR-HMGA2 
reporter107 and 400 ng VP5-Ago2 constructs154,160 in 48-well format using Lipofectamin 2000 
(4.8.1.2). The empty vector VP5 served as a control. 48 h after transfection, cells were lysed 
with Passive Lysis Buffer (Promega) while shaking. Luciferase substrates were purchased 
from PJK Cryosystems and the luciferase activity was measured on the Mithras LB940 
luminometer (Berthold Technologies). The Firefly/Renilla luminescence ratios were 
calculated for each sample and normalized to the ratio in the empty vector control sample.  
 
4.12 Immunofluorescence 
 
The immunofluorescence (IF) were conducted as described previously224. Briefly, 24 h after 
transfection with 300 ng of the plasmids, cells were seeded on microscopy slides in 24-well 
plates to about a confluency of 50 %. Again, after 24 h, cells were first washed twice with 
warm PBS, incubated for 10 min with 3.7 % PFA in PBS at 37°C, stopped with 100 mM glycine 
in PBS for 5 min at 37°C and washed twice with PBS. The cells were then permeabilized with 
0.2 % TX-100 in PBS for 15 min at RT and washed trice with PBS + 0.05 % TX-100 + 1 % BSA. 
Cells were blocked in this solution for 1 h. The cells were incubated in PBS + 0.05 % TX-100 
+ 1 % BSA supplemente4d with the first antibody for 1 h. After four washing steps with the 
blocking solution, cells were again incubated for 1 h with the second antibody, followed by 
four washings. At the end, the slides were mounted with Prolong Gold containing DAPI 
(Thermo Fisher Scientific – Life Technologies). Confocal microscopy was performed on a 
TCSSP8 (Leica Microsystems) equipped with acousto-optical beam splitter, 405 nm laser 
(DAPI), argon laser (488 nm for Alexa 488), and DPSS laser 561 nm (for Alexa 555). 
 
4.13 GeneChip microarray assay 
 
Preparation of the samples for microarray hybridization was performed as described in the 
Affymatrix GeneChip WT PLUS Reagent Kit User Manual (Affimetrix, Inc., Santa Clara, CA, 
USA). Shortly, to generate double-stranded cDNA, 4-100 ng of the IP-RNA were used. ERCC 
spike-in (Thermo Fisher Scientific) were added (1 µl ERCC 1:50,000 per ng input RNA; 1 µl 
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ERCC 1:250,000 per ng precipitated RNA). Of subsequently synthesized cRNA 15 µg were 
purified and reversely transcribed into sense-strand cDNA, where unnatural dUTP residues 
were incorporated. For fragmentation of the sense-stranded cDNA, a combination of uracil 
DNA glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1 (APE 1) followed by a 
terminal labeling with biotin. 3.8 µg of the fragmented and labeled sense-stranded cDNA were 
hybridized to Affymetrix Human Gene 2.1 ST Array Plates. The Affymetrix GeneTitan system 
was used for hybridization, washing, staining and scanning, under control of the Affymetrix 
GeneChip Command Console software v4.2. Processing of the samples was carried out at an 
Affymetrix Service Provider and Core Facility, “KFB – Center of Excellence for Fluorescent 
Bioanalytics” (Regensburg, Germany)160.  
 
4.14 Bioinformatic analysis 
4.14.1 Microarray 
 
The RNA-IP (RIP) microarray data were processed in R version 3.3.0 [R core Team2016] with 
the oligo package (oligo_1.36.0)225 using the built-in Affymetrix annotation 
(pd.hugene.2.1.st_3.14.1). For calibration of samples with different precipitated Ago 
quantities and their associated mRNAs to a fixed mRNA amount, ERCC RNA Spike-In Mix 
(Thermo Fisher Scientific) was added in proportion to the precipitated mRNA amount (4.13). 
Subsequently, the spike-in amounts were used for normalization in bioinformatics analysis. 
Following data quality control, ERCC spike-in intensities were used for vsn normalization of 
the different Affymetrix single color microarrays. Limma was used for analysis of differential 
precipitation in RIP assays. First, data were filtered to contain only transcripts enriched over 
input (log2FC Ago2 WT IP vs input >0), with the result of 4,200 transcripts. With these 
transcripts, cumulative distributions of the log2FC of mutant IP versus WT IP were drawn to 
globally analyze mRNA binding. A further reduction of the transcripts to the ones with a false 
discovery rate of the moderated t-test within limma below 0.3 for all three mutants versus 
WT comparisons helped to focus on the significant changes in mRNA binding. This resulted in 
103 transcripts. In the GEO database www.ncbi.nlm.nih.gov/geo/ the microarray data is 
deposited and assigned the identifier GSE92698160. 
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4.14.2 Sequence alignments  
 
Protein sequences were retrieved from www.uniprot.org and the alignments were performed 
by Clustal Omega (www.ebi.ac.uk/Tools/msa/clustalo/).  
Homo sapiens: Ago1 Q9UL18, Ago2 Q9UKV8, Ago3 Q9H9G7, Ago4 Q9HCK5 
Caenorhabditis elegans: ALG1 G5EES3 
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Mass spectrometry data – phosphorylation sites 
 
Table 9 Potential phosphorylation sites in human Ago2 
 
 
 
Table 10 Potential phosphorylation sites in human Ago1 
 
Peptide Residue [phospho-site] score REPL_1 score REPL_2 score REPL_3
MYSGAGPALAPPAPPPPIQGYAFKPPPRPDFGTSGR Y[2]/S[3] 25.0 25.0
WVSCVSLQALHDALSGR S[136] 34.1 30.0
SFFTASEGCSNPLGGGR S[180]/S[189] 92.5 47.8 23.9
RPASHQTFPLQQESGQTVECTVAQYFK S[307] 43.3 23.8
YPHLPCLQVGQEQK Y[322] 27.2 38.0
SASFNTDPYVR S[387] 45.7 42.7 61.3
VGDTVLGMATQCVQMK T[538]/T[544] 26.1 44.9 30.4
TTPQTLSNLCLK T[555]/T[556] 57.2 45.5 44.9
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[824] 93.6 113.0 102.2
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[828] 78.2 126.0 19.6
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK T[830] 66.4 17.6
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[834] 26.5
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[824]/S[828] 28.4 22.5
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[824]/S[834] 22.0 16.9
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[828]/T[830] 17.9 49.8 18.1
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[828]/S[831] 24.3
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK T[830]/S[831] 43.5 43.9
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[831]/S[834] 24.0
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[828]/T[830]/S[831] 16.0
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[824]/S[828]/T[830] 22.7 31.3 18.8
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[828]/T[830]/S[831]/S[834] 26.5 22.1
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[824]/S[828]/T[830]/S[834] 27.0
Peptide Residue [phospho-site] score REPL_1 score REPL_2 score REPL_3
MEAGPSGAAAGAYLPPLQQVFQAPR S[6] 63.7 59.2 59.7
MEAGPSGAAAGAYLPPLQQVFQAPR Y[13] 45.8 33.2
YPHLPCLQVGQEQK Y[320] 27.2 39.1
HTYLPLEVCNIVAGQR T[335] 52.3
RVGDTLLGMATQCVQV T[536] 32 38.5
TSPQTLSNLCLK T[553]/S[554] 45 41.7
YHLVDKEHDSGEGSHISGQSNGR/DPQALAK S[822] 27.2 82.8 24
YHLVDKEHDSGEGSHISGQSNGR/DPQALAK S[826] 35.3 19.7 31.1
YHLVDKEHDSGEGSHISGQSNGR/DPQALAK S[829] 26.1
YHLVDKEHDSGEGSHISGQSNGR/DPQALAK S[832] 18.4 23.5
YHLVDKEHDSGEGSHISGQSNGR/DPQALAK S[822]/S[826] 29.1
YHLVDKEHDSGEGSHISGQSNGR/DPQALAK S[822]/S[829] 42.6 17.2
YHLVDKEHDSGEGSHISGQSNGR/DPQALAK S[822]/S[832] 18
YHLVDKEHDSGEGSHISGQSNGR/DPQALAK S[829]/S[832] 16.5
YHLVDKEHDSGEGSHISGQSNGR/DPQALAK S[826]/S[829] 37.6 47.7
YHLVDKEHDSGEGSHISGQSNGR/DPQALAK S[826]/S[829]/S[832] 20.3 23.6
YHLVDKEHDSGEGSHISGQSNGR/DPQALAK S[822]/S[826]/S[829] 49.4 20.9
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Table 11 Potential phosphorylation sites in human Ago3 
 
 
 
Table 12 Potential phosphorylation sites in human Ago4 
 
 
  
Peptide Residue [phospho-site] score REPL_1 score REPL_2 score REPL_3
MEIGSAGPAGAQPLLMVPR S[5] 66.7 36.9 31.4
YPHLPCLQVGQEQK Y[323] 27.2 39.1
RVGDTLLGMATQCVQVK T[539] 42.4 32 38.5
TSPQTLSNLCLK T[556] 45 41.7
YHLVDKEHDSAEGSHVSGQSNGR/DPQALAK S[825] 48.2 16 25.7
YHLVDKEHDSAEGSHVSGQSNGR/DPQALAK S[829] 31.9 39.2 39.6
YHLVDKEHDSAEGSHVSGQSNGR/DPQALAK S[832] 28.8 23.5 19.4
YHLVDKEHDSAEGSHVSGQSNGR/DPQALAK S[835] 22.3 16.7
YHLVDKEHDSAEGSHVSGQSNGR/DPQALAK S[825]/S[829] 21.1
YHLVDKEHDSAEGSHVSGQSNGR/DPQALAK S[832]/S[835] 16.5
YHLVDKEHDSAEGSHVSGQSNGR/DPQALAK S[829]/S[832] 32.9 18.8
YHLVDKEHDSAEGSHVSGQSNGR/DPQALAK S[829]/S[835] 24.4
YHLVDKEHDSAEGSHVSGQSNGR/DPQALAK S[825]/S[829]/S[832] 22.3
YHLVDKEHDSAEGSHVSGQSNGR/DPQALAK S[825]/S[832]/S[835] 21.9 23.6
YHLVDKEHDSAEGSHVSGQSNGR/DPQALAK S[825]/S[829]/S[832]/S[835] 15.6
Peptide Residue [phospho-site] score REPL_1 score REPL_2 score REPL_3
YPHLPCLQVGQEQK Y[312] 41.9 27.2 39.1
HTYLPLEVCNIVAGQR T[327] 49.1 52.3
RVGDTLLGMATQCVQVK T[530]/T[536] 26 32 38.5
TSPQTLSNLCLK T[547] 75.6 45 41.7
YHLVDKDHDSAEGSHVSGQSNGR/DPQALAK S[826] 18.1 25.4 19
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Table 13 Potential phosphorylation sites in mouse Ago2 
 
 
 
 
 
 
Peptide Residue [phospho-site] score REPL_1 score REPL_2 score REPL_3
MYSGAGPVLASPAPTTSPIPGYAFKPPPRPDFGTTGR S[3] 28,11
SFFTASEGCSNPLGGGR S[190] 17,16
RPASHQTFPLQQESGQTVECTVAQYFK T[308] 24,42
SASFNTDPYVR S[388] 49.5 54,29
VGDTVLGMATQCVQMK T[545] 20
TTPQTLSNLCLK T[557]
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[825] 75.5 66.2 104,43
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[829] 67.3 85.8 38,68
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK T[831] 18.7
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[832] 48.2 35.1
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[835] 33.7 17.7
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[829]/S[832] 22,82
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[829]/T[831]
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[825]/S[829] 19.8 37.7
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK T[831]/S[832] 37.1
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[825]/S[829]/T[831] 26 46.7 18,43
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[829]/T[831]/S[832] 38.4 15,32
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[829]/T[831]/S[832]/S[835] 17.9 16,28
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[825]/T[831]/S[832]/S[835] 22,46
Peptide Residue [phospho-site] score REPL_4 score REPL_5 score REPL_6
MYSGAGPVLASPAPTTSPIPGYAFKPPPRPDFGTTGR S[3] 20,23 23,85 29,86
SFFTASEGCSNPLGGGR S[190] 23,17
RPASHQTFPLQQESGQTVECTVAQYFK T[308] 19,78
SASFNTDPYVR S[388] 55,8 31,45 66,81
VGDTVLGMATQCVQMK T[545] 16,55
TTPQTLSNLCLK T[557] 15,52
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[825] 84,43 70,89 26,76
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[829] 37,96 34,14 74,8
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK T[831] 36,21
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[832] 14,07 19,14 27,25
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[829]/T[831] 46,03 30,88
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[825]/S[829] 23,64 43,79
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK T[831]/S[832] 27,55
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[825]/S[829]/T[831] 29,15 29,52 22,78
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[829]/T[831]/S[832] 18,18
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[829]/T[831]/S[832]/S[835] 24,67
Peptide Residue [phospho-site] score REPL_7 score REPL_8
MYSGAGPVLASPAPTTSPIPGYAFKPPPRPDFGTTGR S[3] 21,47
SFFTASEGCSNPLGGGR S[190] 32,07
RPASHQTFPLQQESGQTVECTVAQYFK T[308] 34,4
SASFNTDPYVR S[388] 45,06 49,21
VGDTVLGMATQCVQMK T[545] 20,1 39,21
TTPQTLSNLCLK T[557]
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[825] 66,99 96,35
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[829] 85,73 53,59
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK T[831] 17,53
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[832] 14,5 32,34
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[829]/S[832] 14,08
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK T[831]/S[832] 40,3
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[825]/S[829]/T[831] 19 27,62
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[829]/T[831]/S[832] 16,4
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[829]/T[831]/S[832]/S[835] 27,97 32,2
YHLVDKEHDSAEGSHTSGQSNGR/DPQALAK S[825]/T[831]/S[832]/S[835] 24,94
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Table 14 Potential phosphorylation sites in rat Ago2 
 
 
 
Table 15 Potential phosphorylation sites in zebrafish Ago2 
 
 
 
Table 16 Potential phosphorylation sites in C. elegans ALG-1 
 
   
Peptide Residue [phospho-site] score REPL_1 score REPL_2 score REPL_3
MYSGAGPVLASPAPTTSPIPGY Y[2] 24,85 13,65
SFFTASEGCSNPLGGGRE S[190] 30,73
SASFNTDPYVR S[388] 62,28 44,04 42.1
VGDTVLGMATQCVQMK T[545] 20,3 17,35 20.5
TLSNLCLKINVK S[562] 20,99
YHLVDKEHDSAEGSHTSGQSNGR S[825] 91,74 95,58 75.5
YHLVDKEHDSAEGSHTSGQSNGR S[829] 67.9 47,61 58.4
YHLVDKEHDSAEGSHTSGQSNGR S[835] 27.6
YHLVDKEHDSAEGSHTSGQSNGR S[829]/S[832] 23,83
YHLVDKEHDSAEGSHTSGQSNGR S[829]/T[831] 30
YHLVDKEHDSAEGSHTSGQSNGR S[825]/S[829] 61
YHLVDKEHDSAEGSHTSGQSNGR T[831]/S[832] 29,96 21,14
YHLVDKEHDSAEGSHTSGQSNGR S[832]/S[835] 21,57
YHLVDKEHDSAEGSHTSGQSNGR S[825]/S[829]/T[831] 28,63
YHLVDKEHDSAEGSHTSGQSNGR S[825]/S[829]/S[835] 26,33
Peptide Residue [phospho-site] score REPL_1 score REPL_2 score REPL_3
YHLVDKEHDSAEGSHTSGQSNGR S[838] 40.6 48.1 33,83
YHLVDKEHDSAEGSHTSGQSNGR S[842] 29.5 20 41,14
YHLVDKEHDSAEGSHTSGQSNGR T[844] 14,02
Peptide Residue [phospho-site] score REPL_1 score REPL_2 score REPL_3
TTPQTLSNLCLK T[720] 38,73 30,13
YHLVDR/EHDSGEGSQPSGTSEDTTLSNMAR S[988] 85.2 96,3
YHLVDR/EHDSGEGSQPSGTSEDTTLSNMAR S[992] 114 111,55 123,47
YHLVDR/EHDSGEGSQPSGTSEDTTLSNMAR S[995] 35 28,2
YHLVDR/EHDSGEGSQPSGTSEDTTLSNMAR T[997] 20.4 26,96 27,47
YHLVDR/EHDSGEGSQPSGTSEDTTLSNMAR S[988]/S[992] 52,76
YHLVDR/EHDSGEGSQPSGTSEDTTLSNMAR S[992]/S[995] 67.4 60,28 56,15
YHLVDR/EHDSGEGSQPSGTSEDTTLSNMAR S[995]/T[997] 41.2 44,62
YHLVDR/EHDSGEGSQPSGTSEDTTLSNMAR T[997]/S[998] 35,14 38,43
YHLVDR/EHDSGEGSQPSGTSEDTTLSNMAR S[992]/S[995]/T[997] 39.1 58,87 56,68
YHLVDR/EHDSGEGSQPSGTSEDTTLSNMAR S[995]/T[997]/S[998] 21 42,8 38,64
YHLVDR/EHDSGEGSQPSGTSEDTTLSNMAR S[988]/S[992]/S[995] 27,49 17,25
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List of Abbreviations 
Units were abbreviated according to the International System of Units. Chemical names not 
indicated below were abbreviated according to the International Union of Pure and Applied 
Chemistry (IUPAC) recommendations. 
A / Ala Alanine 
aa amino acid 
AEBSF  4-(2-aminoethyl) benzenesulfonyl .uoride hydrochloride 
Ago  Argonaute 
Ago-APP Ago affnity purification by peptides 
Amp  ampicillin 
ANKRD28, 44, 52 Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat 
subunit A-B// Ankyrin repeat domain-containing protein 28, 44, 52 
APS ammonium persulphate 
ATP adenosine triphosphate 
bp  base pair(s) 
BSA  bovine serum albumin 
C / Cys Cysteine 
C. elegans  Caenorhabditis elegans 
cDNA  complementary DNA 
CDS  coding sequence 
CoIP  co-immunoprecipitation 
CSNK1A1 Casein kinase I isoform alpha 
CTD C-terminal domain 
D. melanogaster  Drosophila melanogaster 
Da  Dalton 
Del deletion 
DMEM  Dulbecco’s Modified Eagle’s Medium 
DNA  deoxyribonucleic acid 
dNTP  deoxynucleoside triphosphate 
ds double-stranded 
dsRBD  double-stranded RNA binding domain 
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dT  desoxythymidine 
DTT dithiothreitol 
E / Glu Glutamate 
EDC  1-ethyl-3-(3-dimethyl-aminopropyl)-carbodiimid 
EDTA  ethylenediaminetetraacetic acid 
EGFR epithelial growth factor receptor 
eIF  eukaryotic initiation factor 
ERK  extracellular signal–regulated protein kinases 
EtBr ethidium bromide 
Exp  Exportin 
F / Phe Phenylalanine 
FBS  fetal bovie serum 
G / Gly Glycine 
g  gram 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
GDP  guanosine diphosphate 
GFP  green .uorescent protein 
GSH  glutathione 
GSK3 glycogen synthase kinase 3_ 
GST glutahione-S-transferase 
GTP  guanosine triphosphate 
H / His Histidine 
h  hour 
H. sapiens  Homo sapiens 
HA  hemagglutinin 
HEK 293T  human embryonic kidney 293T 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HMGA2  high mobility group AT hook 2 
HSP90  heat shock protein 90 
Imp  Importin 
IP  immunoprecipitation 
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IPTG  isopropyl _-D-1-thiogalactopyranoside 
K / Lys Lysine 
k  kilo 
kb  kilobase 
L / Leu Leucine 
l  liter 
LB  lysogeny broth 
M / Met Methionine 
M  molar 
MAPK  MAP (mitogen-activated protein) kinase 
MAP3K7 / TAK1 Mitogen-activated protein kinase kinase kinase 7 
MAPKAPK2  MAP-activated protein kinase 2 
MCS  multiple cloning site 
min  minute 
miRISC  miRNA induced silencing complex 
miRNA  microRNA 
miRNP  micro-ribonucleoprotein 
MKK  MAPK kinase 
mRNA  messenger RNA 
MS  mass spectrometry, mass spectrometric 
Neo  neomycine 
NES  nuclear localization signal 
NMR  nuclear magnetic resonance 
nt  nucleotides(s) 
o/n  over night 
OD  optical density 
ORF  open reading frame 
P / Pro Proline 
PABP  poly(A)-binding protein 
PACT  protein activator of the interferon-induced protein kinase 
PAGE  polyacrylamide gel electrophoresis 
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PAM2  PABP interacting motif 2 
PAN2/3  PAB-dependent poly(A)-specific ribonuclease subunit 2/3 
PAR-CLIP  Photoactivatable-Ribonucleoside-Enhanced Crosslinking and IP 
PAZ  PIWI-Argonaute-Zwille 
P-bodies  processing bodies 
PBS  Phosphate buffered saline 
PBS(-T)  phosphate-buffered saline (containing Tween 20) 
PCR  polymerase chain reaction 
piRNA  Piwi-interacting RNA 
piRNA  PIWI-interacting RNA 
PIWI  P-element-induced wimpy testes 
PNK  polynucleotide kinase 
PPP6C Serine/threonine-protein phosphatase 6 catalytic subunit 
PP6R1-3 Serine/threonine-protein phosphatase 6 regulatory subunit 1-3 
pre-miRNA  precursor miRNA 
pri-miRNA  primary miRNA 
PTGS  post-transcriptional gene silencing 
PTM  post-translational modification 
PTP1B  protein tyrosine phosphatase 1B 
Q / Gln Glutamine 
qRT-PCR  quantitative real-time polymerase chain reaction 
R / Arg Arginine 
RAS  rat sarcoma 
RIPA  radioimmunoprecipitation assay 
RISC  RNA-induced silencing complex 
RNA  ribonucleic acid 
RNAi  RNA interference 
RNP  ribonucleoprotein 
rpm  revolutions per minute 
RRM  RNA recognition motif 
RT  room temperature 
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S / Ser Serine 
S. pombe Schizosaccaromyces pombe 
S. cerevisiae  Saccharomyces cerevisiae 
SDS  sodium dodecyl sulfate 
sec  second 
shRNA  short hairpin RNA 
siRNA  small interfering RNA 
snoRNA  small nucleolar RNA 
SRM  selected reaction monitoring 
ss  single-stranded 
SSC  saline-sodium citrate buffer 
T / Thr Threonine 
TBE  Tris/Borate/EDTA buffer 
TBS  Tris buffered saline 
TBS(-T)  Tris-buffered saline (containing Tween 20) 
TEMED  tetramethylethylenediamine 
TRBP  transactivating response RNA binding protein 
TRIM71  tripartite motif-containing protein 71 
tRNA  transfer RNA 
UBA  ubiquitin-associated 
UTP  uridine triphosphate 
UTR  untranslated region 
V / Val Valine 
W / Trp Tryptophan 
w/v  weight per volume 
wt / WT wild type 
Y / Tyr Tyrosine 
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